<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="review-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Biochem</journal-id><journal-title>BMC Biochemistry</journal-title><issn pub-type="epub">1471-2091</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">2106371</article-id><article-id pub-id-type="pmid">18047744</article-id><article-id pub-id-type="publisher-id">1471-2091-8-S1-S7</article-id><article-id pub-id-type="doi">10.1186/1471-2091-8-S1-S7</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Roles and potential therapeutic targets of the ubiquitin proteasome system in muscle wasting</article-title></title-group><contrib-group><contrib id="A1" contrib-type="author"><name><surname>Nury</surname><given-names>David</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>david.nury@crbm.cnrs.fr</email></contrib><contrib id="A2" contrib-type="author"><name><surname>Doucet</surname><given-names>Christine</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>christine.doucet@crbm.cnrs.fr</email></contrib><contrib id="A3" corresp="yes" contrib-type="author"><name><surname>Coux</surname><given-names>Olivier</given-names></name><xref ref-type="aff" rid="I1">1</xref><xref ref-type="aff" rid="I3">3</xref><email>olivier.coux@crbm.cnrs.fr</email></contrib></contrib-group><aff id="I1"><label>1</label>CRBM-CNRS UMR5237, IFR22, 1919 route de Mende, 34000 Montpellier, France</aff><aff id="I2"><label>2</label>Molecular and Cell Biology Laboratory, Salk Institute, 10010 North Torrey Pines Road, CA 92037-1099 La Jolla, USA</aff><aff id="I3"><label>3</label>CRBM-CNRS, 1919 route de Mende, 34293 Montpellier cedex 5, France</aff><pub-date pub-type="collection"><year>2007</year></pub-date><pub-date pub-type="epub"><day>22</day><month>11</month><year>2007</year></pub-date><volume>8</volume><issue>Suppl 1</issue><supplement><named-content content-type="supplement-title">Ubiquitin-Proteasome System in Disease Part 1</named-content><named-content content-type="supplement-editor">Edited by John Mayer and Rob Layfield</named-content></supplement><fpage>S7</fpage><lpage>S7</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2091/8/S1/S7"/><permissions><copyright-statement>Copyright &#x000a9; 2007 Nury et al.; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2007</copyright-year><copyright-holder>Nury et al.; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an open access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author>
               Nury
               David
               
               david.nury@crbm.cnrs.fr
            </dc:author><dc:title>
            Roles and potential therapeutic targets of the ubiquitin proteasome system in muscle wasting
         </dc:title><dc:date>2007</dc:date><dcterms:bibliographicCitation>BMC Biochemistry 8(Suppl 1): S7-. (2007)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2091(2007)8:Suppl 1&#x0003c;S7&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2091</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><p>Muscle wasting, characterized by the loss of protein mass in myofibers, is in most cases largely due to the activation of intracellular protein degradation by the ubiquitin proteasome system (UPS). During the last decade, mechanisms contributing to this activation have been unraveled and key mediators of this process identified. Even though much remains to be understood, the available information already suggests screens for new compounds inhibiting these mechanisms and highlights the potential for pharmaceutical drugs able to treat muscle wasting when it becomes deleterious. This review presents an overview of the main pathways contributing to UPS activation in muscle and describes the present state of efforts made to develop new strategies aimed at blocking or slowing muscle wasting.</p><p><bold>Publication history: </bold>Republished from Current BioData's Targeted Proteins database (TPdb; <ext-link ext-link-type="uri" xlink:href="http://www.targetedproteinsdb.com"/>).</p></abstract></article-meta></front><body><sec><title>Roles of the UPS in muscle wasting</title><p>Skeletal muscle wasting, or atrophy, is characterized by a reduction in muscle mass due to an imbalance between protein synthesis and degradation, resulting in a loss of net protein content in the myofibers (see reviews cited in [<xref ref-type="bibr" rid="B1">1</xref>] for more information). Even though there is clear evidence that a reduction in protein synthesis participates in this process, there is now a large body of experiments showing that a central mechanism in muscle wasting is increased intracellular proteolysis, due in particular (but not exclusively [<xref ref-type="bibr" rid="B2">2</xref>]) to the activation of the ubiquitin proteasome system (UPS) [<xref ref-type="bibr" rid="B3">3</xref>,<xref ref-type="bibr" rid="B4">4</xref>].</p><p>Muscle wasting occurs in a variety of physiological or pathological circumstances, including inactivity or muscle disuse, fasting and many diseases such as cancer, renal failure or trauma [<xref ref-type="bibr" rid="B5">5</xref>]. As skeletal muscle is the major protein reservoir of the body, muscle wasting has beneficial effects in its initial stage since it provides the organism with an ample pool of free amino acids that can be reused for energy production or protein synthesis in vital organs [<xref ref-type="bibr" rid="B6">6</xref>]. However, in a variety of pathologies such as cancer, sepsis and diabetes, this catabolic state is maintained over a long period of time and can become life-threatening; this condition is often referred to as cachexia [<xref ref-type="bibr" rid="B7">7</xref>].</p><p>The aim of this review is to provide an overview on the role of the UPS in muscle wasting. For the sake of space, only the mechanisms presently thought to be common to most types of muscle wasting are described, and the reader is invited to refer to numerous recent reviews for more detailed information on specific topics [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B8">8</xref>-<xref ref-type="bibr" rid="B11">11</xref>]. It should be noted that most of the results described in this review were obtained with animal models of severe muscle wasting. Therefore, extrapolation to humans of the mechanisms presented below should be treated with caution.</p><sec><title>UPS components involved in muscle wasting</title><p>Initial studies, mostly performed using muscles isolated from animals subjected to induced muscle wasting, led to the conclusion in the early 1990s that increased ATP-dependent proteolysis accounted for a large part of muscle protein loss in several muscle wasting models [<xref ref-type="bibr" rid="B12">12</xref>]. After the subsequent recognition that the UPS (initially discovered and dissected in rabbit reticulocyte lysate [<xref ref-type="bibr" rid="B13">13</xref>-<xref ref-type="bibr" rid="B15">15</xref>]) was responsible for ATP-dependent proteolysis in mammalian cells [<xref ref-type="bibr" rid="B16">16</xref>], and the demonstration that its general inhibition by proteasome inhibitors reduces the accelerated proteolysis in atrophying muscles [<xref ref-type="bibr" rid="B17">17</xref>], several groups turned to the analysis of expression of individual UPS components in different experimental models of muscle wasting (see Table <xref ref-type="table" rid="T1">1</xref>).</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Main conditions used to induce muscle wasting in animals (mice and rats) and the variation of key components involved in UPS activation. Please note that the models in this table were generated only for the experiments: muscle wasting was induced in normal animals by various treatments and the molecular mechanisms subsequently analyzed.</p></caption><table frame="hsides" rules="groups"><tbody><tr><td><bold>Main models of muscle wasting</bold></td><td colspan="6"><bold>Variation of key components involved in UPS activation</bold></td></tr><tr><td><hr></hr></td><td colspan="6"><hr></hr></td></tr><tr><td></td><td><bold>UPS mRNAs</bold></td><td><bold>N-end rule pathway</bold></td><td><bold>NF&#x003ba;B activity</bold></td><td><bold>MuRF-1</bold></td><td><bold>MAFbx</bold></td><td><bold>Selected reference</bold></td></tr><tr><td><bold>Cancer cachexia</bold></td><td><graphic xlink:href="1471-2091-8-S1-S7-i1.gif"/></td><td><graphic xlink:href="1471-2091-8-S1-S7-i1.gif"/></td><td><graphic xlink:href="1471-2091-8-S1-S7-i1.gif"/></td><td><graphic xlink:href="1471-2091-8-S1-S7-i1.gif"/></td><td><graphic xlink:href="1471-2091-8-S1-S7-i1.gif"/></td><td>[84,100]</td></tr><tr><td><bold>Sepsis</bold></td><td><graphic xlink:href="1471-2091-8-S1-S7-i1.gif"/></td><td><graphic xlink:href="1471-2091-8-S1-S7-i1.gif"/></td><td><graphic xlink:href="1471-2091-8-S1-S7-i1.gif"/></td><td><graphic xlink:href="1471-2091-8-S1-S7-i1.gif"/></td><td><graphic xlink:href="1471-2091-8-S1-S7-i1.gif"/></td><td>[101,102]</td></tr><tr><td><bold>Hindlimb suspension</bold></td><td><graphic xlink:href="1471-2091-8-S1-S7-i1.gif"/></td><td><graphic xlink:href="1471-2091-8-S1-S7-i1.gif"/></td><td><graphic xlink:href="1471-2091-8-S1-S7-i1.gif"/></td><td><graphic xlink:href="1471-2091-8-S1-S7-i1.gif"/></td><td><graphic xlink:href="1471-2091-8-S1-S7-i1.gif"/></td><td>[89,103]</td></tr><tr><td><bold>Denervation</bold></td><td><graphic xlink:href="1471-2091-8-S1-S7-i1.gif"/></td><td>?</td><td><graphic xlink:href="1471-2091-8-S1-S7-i1.gif"/></td><td><graphic xlink:href="1471-2091-8-S1-S7-i1.gif"/></td><td><graphic xlink:href="1471-2091-8-S1-S7-i1.gif"/></td><td>[17,31,104]</td></tr><tr><td><bold>Hyperthyroidism</bold></td><td><graphic xlink:href="1471-2091-8-S1-S7-i1.gif"/></td><td>?</td><td><graphic xlink:href="1471-2091-8-S1-S7-i1.gif"/></td><td><graphic xlink:href="1471-2091-8-S1-S7-i1.gif"/></td><td><graphic xlink:href="1471-2091-8-S1-S7-i1.gif"/></td><td>[17,105]</td></tr><tr><td><bold>Burn injuries</bold></td><td><graphic xlink:href="1471-2091-8-S1-S7-i1.gif"/></td><td><graphic xlink:href="1471-2091-8-S1-S7-i1.gif"/></td><td><graphic xlink:href="1471-2091-8-S1-S7-i1.gif"/></td><td><graphic xlink:href="1471-2091-8-S1-S7-i1.gif"/></td><td><graphic xlink:href="1471-2091-8-S1-S7-i1.gif"/></td><td>[106,107]</td></tr><tr><td><bold>Cirrhosis</bold></td><td><graphic xlink:href="1471-2091-8-S1-S7-i1.gif"/></td><td>?</td><td><graphic xlink:href="1471-2091-8-S1-S7-i1.gif"/></td><td><graphic xlink:href="1471-2091-8-S1-S7-i1.gif"/></td><td><graphic xlink:href="1471-2091-8-S1-S7-i1.gif"/></td><td>[108,109]</td></tr><tr><td><bold>Starvation</bold></td><td><graphic xlink:href="1471-2091-8-S1-S7-i1.gif"/></td><td><graphic xlink:href="1471-2091-8-S1-S7-i1.gif"/></td><td><graphic xlink:href="1471-2091-8-S1-S7-i1.gif"/></td><td><graphic xlink:href="1471-2091-8-S1-S7-i1.gif"/></td><td><graphic xlink:href="1471-2091-8-S1-S7-i1.gif"/></td><td>[110,111]</td></tr><tr><td><bold>Diabetes</bold></td><td><graphic xlink:href="1471-2091-8-S1-S7-i1.gif"/></td><td><graphic xlink:href="1471-2091-8-S1-S7-i1.gif"/></td><td><graphic xlink:href="1471-2091-8-S1-S7-i1.gif"/></td><td><graphic xlink:href="1471-2091-8-S1-S7-i1.gif"/></td><td><graphic xlink:href="1471-2091-8-S1-S7-i1.gif"/></td><td>[56,105,112]</td></tr><tr><td><bold>Uremia</bold></td><td><graphic xlink:href="1471-2091-8-S1-S7-i1.gif"/></td><td>?</td><td><graphic xlink:href="1471-2091-8-S1-S7-i1.gif"/></td><td><graphic xlink:href="1471-2091-8-S1-S7-i1.gif"/></td><td><graphic xlink:href="1471-2091-8-S1-S7-i1.gif"/></td><td>[37,113]</td></tr></tbody></table><table-wrap-foot><p><graphic xlink:href="1471-2091-8-S1-S7-i1.gif"/>: upregulation; ?: not determined or unclear.</p></table-wrap-foot></table-wrap><p>In general, the UPS functions in two distinct steps to degrade intracellular proteins. First, the substrate protein is labeled by covalent linkage of polyubiquitin (polyUb) chain(s) to one or several lysine residue(s) by the action of an enzymatic cascade involving three types of factors, referred to as E1, E2s and E3s [<xref ref-type="bibr" rid="B18">18</xref>]. In this reaction, the E3s act as substrate recognition factors and are thus the main determinants of the specificity of the UPS [<xref ref-type="bibr" rid="B19">19</xref>]. Consequently, their number is very high, with a rough estimation of several hundred E3s present in the genome, depending on the organism [<xref ref-type="bibr" rid="B20">20</xref>]. The second step in protein degradation by the UPS is the degradation of the polyubiquitylated substrate by the 26S proteasome, a large compartmentalized protease comprising the 20S proteasome, which contains the proteolytic active sites in its internal catalytic chamber, and the 19S regulatory complex, which is essential for degradation of ubiquitylated proteins [<xref ref-type="bibr" rid="B21">21</xref>,<xref ref-type="bibr" rid="B22">22</xref>].</p><p>A common theme in most models of muscle wasting is a significant increase at the mRNA level of many components of the UPS. These include ubiquitin (Ub), E2s, proteasome subunits (20S and 19S), deubiquitylating enzymes and certain E3s [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B23">23</xref>-<xref ref-type="bibr" rid="B25">25</xref>]. The accepted interpretation is that this upregulation of UPS mRNAs participates in the overall activation of the UPS observed during muscle wasting, in line with the fact that an increase in (i) the rate of Ub conjugation to proteins, (ii) the intracellular level of ubiquitylated proteins and (iii) proteasome activity has been described in most muscle wasting conditions [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B8">8</xref>]; see also Table <xref ref-type="table" rid="T1">1</xref>]. However, it should be noted that, despite the upregulation of their corresponding mRNA, the level of many UPS proteins does not appear significantly altered during muscle wasting. The reasons for this discrepancy are unclear, but an interesting hypothesis is that the increased synthesis of these proteins is compensated by an accelerated turnover under the conditions analyzed.</p><p>The first specific UPS pathway described to be involved in muscle wasting was the &#x02018;N-end rule&#x02019; pathway ([<xref ref-type="bibr" rid="B26">26</xref>,<xref ref-type="bibr" rid="B27">27</xref>]; see also section on <italic>Substrates of the UPS during muscle wasting</italic>), which rapidly degrades proteins with destabilizing N-terminal residues (see [<xref ref-type="bibr" rid="B28">28</xref>] for review). In mammals, this pathway involves a specific E2 (E2-14K) and several E3 isoforms [<xref ref-type="bibr" rid="B29">29</xref>], among which E3&#x003b1;-II (also known as UBR2) is increased in skeletal muscle during cachexia [<xref ref-type="bibr" rid="B27">27</xref>]. The specific inhibition of this E3 reduces the rate of ubiquitylation of soluble or model proteins in muscle extracts from tumor-bearing or septic rats, as well as in C2C12 cell extracts [<xref ref-type="bibr" rid="B26">26</xref>,<xref ref-type="bibr" rid="B27">27</xref>].</p><p>Transcriptome analyses showed that two other types of E3 or E3 components are upregulated in most muscle wasting models. These are the F-box component MAFbx (also known as Atrogin-1) of the SCF<sup>MAFbx</sup> E3 and the MuRF family of RING finger E3s [<xref ref-type="bibr" rid="B30">30</xref>,<xref ref-type="bibr" rid="B31">31</xref>], which interact with and possibly ubiquitylate a variety of myofibrillar proteins [<xref ref-type="bibr" rid="B32">32</xref>,<xref ref-type="bibr" rid="B33">33</xref>]. Expression of MAFbx and MuRF-1 mRNAs increases dramatically in catabolic states and mice deficient in either of them are partially resistant to denervation atrophy [<xref ref-type="bibr" rid="B31">31</xref>]. Therefore, MAFbx and MuRF-1 play a crucial role in the loss of muscle proteins and their mRNAs are now considered to be specific atrophic markers.</p></sec><sec><title>Substrates of the UPS during muscle wasting</title><p>The major proteins in muscle are the myofibrillar components; however, although monomeric actin and myosin can be degraded by the UPS, it is assumed that this is not the case in intact myofibers since specific interactions between these proteins protects them from degradation by this system [<xref ref-type="bibr" rid="B34">34</xref>]. Thus, an early step in muscle wasting must be the dissociation or at least the destabilization of the myofibrils, a process in which non-UPS proteases shown to be involved in muscle wasting (such as calpains [<xref ref-type="bibr" rid="B35">35</xref>,<xref ref-type="bibr" rid="B36">36</xref>], caspase 3 [<xref ref-type="bibr" rid="B37">37</xref>] or cathepsin L [<xref ref-type="bibr" rid="B38">38</xref>]) probably play a key role. Though the early involvement of non-UPS proteases in the destabilization of myofibrils has not been formally demonstrated, this hypothesis is likely since it helps to explain the observed role of the UPS N-end rule pathway in muscle wasting. Indeed, this pathway requires the substrate to expose a destabilizing N-terminal residue [<xref ref-type="bibr" rid="B28">28</xref>], a feature that is rare for native cellular proteins; however, polypeptides with a destabilizing N-terminal residue can be produced by proteolytic cleavage of native proteins by cellular proteases [<xref ref-type="bibr" rid="B39">39</xref>].</p><p>Another mechanism that controls myofibril organization involves the sarcomeric scaffold protein titin, which possesses a protein kinase domain essential for sarcomere integrity [<xref ref-type="bibr" rid="B40">40</xref>,<xref ref-type="bibr" rid="B41">41</xref>]. Interestingly, the activity of this domain is modulated by mechanical strain [<xref ref-type="bibr" rid="B42">42</xref>], allowing titin to convert tension forces into molecular signals. This function controls both the intracellular level and localization of the RING finger E3 MuRF-2 (a protein closely related to MuRF-1), which is associated with titin in the sarcomeres through interaction with the UBD (Ub binding domain [<xref ref-type="bibr" rid="B43">43</xref>])-containing proteins Nbr1 and p62, and is translocated to the nucleus upon muscle inactivity [<xref ref-type="bibr" rid="B44">44</xref>]. Nuclear localization of MuRF-2 in turn leads to nuclear exclusion of SRF (serum response factor) [<xref ref-type="bibr" rid="B44">44</xref>], a transcription factor central to muscle response to hypertrophic stimuli. Thus, titin appears to be an important relay in the control of muscle disuse atrophy, since it is able to couple mechanical inactivity with muscle wasting by triggering macromolecular rearrangements of sarcomeres and altering muscle transcriptional programs. The importance of the titin&#x02013;Nbr1&#x02013;p62&#x02013;MuRF-2 interaction is underlined by a human mutation disrupting binding of Nbr1 to titin, which causes an autosomal dominant muscle disease called heredity myopathy with early respiratory failure (HMERF) [<xref ref-type="bibr" rid="B44">44</xref>]. In muscle biopsies of HMERF patients, the structure of sarcomeres is altered and the localization of Nbr1, p62 and MuRF-2 is abnormal [<xref ref-type="bibr" rid="B44">44</xref>].</p><p>In addition to these mechanisms, the crucial roles of MAFbx and MuRF-1 during atrophy indicate that these E3s target key negative regulators of muscle wasting for degradation. However, only a few actual or potential substrates have been identified for these E3s and the relevance of these substrates for muscle wasting remains unclear (see <italic>Signaling pathways involved in muscle wasting)</italic>.</p></sec><sec><title>Signaling pathways involved in muscle wasting</title><p>Glucocorticoids are known to be important mediators of muscle wasting in various catabolic conditions [<xref ref-type="bibr" rid="B5">5</xref>]; indeed, dexamethasone triggers upregulation of various UPS components [<xref ref-type="bibr" rid="B45">45</xref>]. However, the underlying mechanisms of glucocorticoid signaling in muscle wasting are not yet fully understood [<xref ref-type="bibr" rid="B23">23</xref>].</p><p>Presently, two families of transcription factors have been clearly identified as crucial positive mediators of muscle wasting: the FoxO (forkhead box O) transcription factors and NF&#x003ba;B [<xref ref-type="bibr" rid="B9">9</xref>]. Of note, these factors are involved in the control of expression of the E3s MuRF-1 and MAFbx [<xref ref-type="bibr" rid="B46">46</xref>-<xref ref-type="bibr" rid="B48">48</xref>].</p><p>PI3K is activated by anabolic signals triggered by insulin or IGF-1 upon binding to their receptors, which in turn activates Akt [<xref ref-type="bibr" rid="B49">49</xref>] (a kinase central to muscle hypertrophy), as shown in transgenic mice in which an active form of Akt can be inducibly expressed in adult skeletal muscle [<xref ref-type="bibr" rid="B50">50</xref>]. Besides its function in stimulating protein synthesis via mTOR and GSK3 [<xref ref-type="bibr" rid="B9">9</xref>], a crucial role for activated Akt is to phosphorylate FoxO [<xref ref-type="bibr" rid="B46">46</xref>,<xref ref-type="bibr" rid="B47">47</xref>,<xref ref-type="bibr" rid="B51">51</xref>], leading to transcriptional inactivation of FoxO due to its release from DNA and 14-3-3 protein-mediated cytoplasmic sequestration (see [<xref ref-type="bibr" rid="B52">52</xref>] for review), and to subsequent inhibition of muscle wasting. In many systemic diseases, including diabetes, cancer and renal failure, low circulating levels of insulin and IGF-1, or resistance to their action, contribute to muscle wasting via inactivation of the PI3K/Akt pathway, which leads to the subsequent dephosphorylation and activation of FoxO [<xref ref-type="bibr" rid="B53">53</xref>-<xref ref-type="bibr" rid="B56">56</xref>]. Interestingly, it has recently been shown that myostatin treatment can also trigger the same effect in mice [<xref ref-type="bibr" rid="B57">57</xref>]. Myostatin is a TGF&#x003b2; super-family member that acts as a negative regulator of muscle growth and is implicated in several forms of muscle wasting [<xref ref-type="bibr" rid="B58">58</xref>]. Myostatin signaling reverses the IGF-1/PI3K/Akt pathway by inhibiting phosphorylation of Akt, leading to activation of FoxO and thereby activation of E2-14K, MuRF-1 and MAFbx [<xref ref-type="bibr" rid="B57">57</xref>].</p><p>In many disease states, stress or inflammatory cytokines such as tumor necrosis factor alpha (TNF&#x003b1;) are produced [<xref ref-type="bibr" rid="B59">59</xref>]. Stimulation of their receptors activates the IKK kinase, which in turn phosphorylates the NF&#x003ba;B inhibitor I&#x003ba;B&#x003b1;, promoting its degradation by the UPS. This leads to the release of NF&#x003ba;B, which migrates to the nucleus to activate its target genes [<xref ref-type="bibr" rid="B60">60</xref>]. Demonstration of a role for this pathway in muscle wasting comes from many observations, including the fact that constitutive activation of IKK in transgenic mice triggered both a decrease in total muscle mass and an increase in atrophy markers, which were reversed by expression of I&#x003ba;B&#x003b1; [<xref ref-type="bibr" rid="B48">48</xref>]. A further observation supporting a role for this pathway in muscle wasting is that direct inhibition of NF&#x003ba;B inhibited cachexia in a mouse tumor model [<xref ref-type="bibr" rid="B61">61</xref>]. In addition, in cancer cachexia, tumor-derived factors such as proteolysis-inducing factor (PIF) [<xref ref-type="bibr" rid="B62">62</xref>,<xref ref-type="bibr" rid="B63">63</xref>], or elevated levels of endogenous factors such as angiotensin I and II, are thought to contribute to muscle atrophy through activation of the NF&#x003ba;B pathway. Supporting evidence comes from the fact that these factors induce increased expression of UPS components (proteasome subunits, E2-14K) and stimulate protein degradation in murine C2C12 myotubes in a manner requiring I&#x003ba;B&#x003b1; degradation and nuclear translocation of NF&#x003ba;B [<xref ref-type="bibr" rid="B64">64</xref>,<xref ref-type="bibr" rid="B65">65</xref>]. Interestingly, although activation of NF&#x003ba;B is also required for muscle disuse atrophy, the NF&#x003ba;B family members that are activated appear distinct from those activated by the TNF&#x003b1; pathway [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B66">66</xref>].</p><p>NF&#x003ba;B and FoxO are thus key players in the activation of muscle wasting. Interestingly, their known targets include MuRF-1 and MAFbx for FoxO [<xref ref-type="bibr" rid="B46">46</xref>,<xref ref-type="bibr" rid="B47">47</xref>], and MuRF-1 for NF&#x003ba;B [<xref ref-type="bibr" rid="B48">48</xref>]. However, as mentioned in the section on <italic>Substrates of the UPS during muscle wasting</italic>, the key substrates of these E3s in muscle wasting are unclear. Nevertheless, one hypothesis is that induction of MuRF-1 activity is important for the destabilization of myofibrillar complexes required for the subsequent degradation of myofibrillar proteins. Indeed, the interaction between MuRF-1 and titin has been shown to be important for sarcomere stability [<xref ref-type="bibr" rid="B67">67</xref>]. Furthermore, in yeast two-hybrid screens, MuRF-1 interacts with several myofibrillar proteins (titin, nebulin, the nebulin-related protein NRAP, troponin-I, troponin-T, myosin light chain 2, myotilin and T-cap) [<xref ref-type="bibr" rid="B33">33</xref>], suggesting that this E3 can mediate their ubiquitylation and degradation in muscle. MuRF-1-mediated ubiquitylation and degradation, however, has only been proven for troponin I [<xref ref-type="bibr" rid="B68">68</xref>] and possibly for myosin light chain 2 [<xref ref-type="bibr" rid="B33">33</xref>] in cardiac tissue. The lack of clear results regarding the role of MuRF-1 in the degradation of its other interactors could be due to its functional redundancy with MuRF-2.</p><p>The known targets of MAFbx (calcineurin A [<xref ref-type="bibr" rid="B32">32</xref>] and MyoD [<xref ref-type="bibr" rid="B69">69</xref>])) are unlikely to be crucial for muscle wasting, since calcineurin A does not appear to affect myofiber size [<xref ref-type="bibr" rid="B70">70</xref>] and MyoD is involved in muscle cell differentiation. The key substrates of MAFbx in muscle wasting thus remain to be identified. Interestingly, however, TNF&#x003b1;/NF&#x003ba;B signaling reduces both the level of MyoD mRNA [<xref ref-type="bibr" rid="B48">48</xref>] and the stability of MyoD [<xref ref-type="bibr" rid="B71">71</xref>], and forced expression of MAFbx inhibits the formation of myotubes in an <italic>in vitro</italic> model of muscle differentiation [<xref ref-type="bibr" rid="B69">69</xref>]. Thus, the role of MAFbx in the down-regulation of MyoD could in fact be indirectly important for muscle wasting, since the inactivation of MyoD functions necessary for the differentiation of muscle satellite cells possibly inhibits muscle regeneration.</p></sec><sec><title>Concluding remarks</title><p>In this brief overview, we have summarized the role of the UPS as an essential mediator of muscle wasting. Even though much remains to be understood before a complete picture of the intricate mechanisms controlling muscle atrophy can emerge, our knowledge to date already suffices to demonstrate that the UPS is an attractive potential target for therapeutic treatments aimed at slowing down muscle atrophy when it becomes harmful to the organism [<xref ref-type="bibr" rid="B5">5</xref>]. The different levels of possible therapeutic intervention are discussed in the section on <italic>Potential targets and drugs for muscle wasting therapy</italic>.</p></sec></sec><sec><title>Analysis of muscle wasting: models, knockouts and assays</title><sec><title>Main models of muscle wasting</title><p>Muscle wasting occurs when the overall rate of protein proteolysis exceeds in a sustained manner that of protein synthesis in muscle. Since a variety of physiological and pathological conditions can influence the equilibrium between these two processes, several animal (mostly murine) models have been developed (see Table <xref ref-type="table" rid="T1">1</xref>) to analyze the mechanisms of muscle mass loss in these different conditions [<xref ref-type="bibr" rid="B72">72</xref>]. For example, cancer, sepsis and cirrhosis are inflammatory conditions that induce muscle wasting through the inhibition of anabolic pathways and the secretion of cytokines (IL1, TNF&#x003b1;) or catabolic factors (PIF), while hindlimb suspension, denervation and sarcopenia are conditions in which disuse atrophy is present. In most models, despite variations in the extent of involvement of the UPS relative to other processes (including other proteolytic systems), activation of UPS-dependent proteolysis transpires to be a crucial event [<xref ref-type="bibr" rid="B6">6</xref>]. Moreover, as described in the section on <italic>Roles of the UPS in muscle wasting</italic>, biochemical and molecular analyses have determined that a convergent mechanism for this activation is the upregulation of crucial ubiquitylation pathways involving the N-End rule E3s as well as the E3s SCF<sup>MAFbx</sup> and MuRF-1 [<xref ref-type="bibr" rid="B73">73</xref>], even though the substrates of these enzymes during muscle wasting remain unclear at present.</p></sec><sec><title>Knockouts of components involved in muscle wasting</title><p>Several mouse strains deficient in components involved in muscle wasting have been constructed and tested for their protection against muscle atrophy (see Table <xref ref-type="table" rid="T2">2</xref>). Manipulation of the N-end rule pathway, by deletion of the genes encoding either E2-14K or the E3 UBR1 [<xref ref-type="bibr" rid="B74">74</xref>,<xref ref-type="bibr" rid="B75">75</xref>], did not significantly impair muscle wasting, probably because of the functional redundancy between the many components of this pathway [<xref ref-type="bibr" rid="B29">29</xref>] and/or because this pathway is only responsible for the breakdown of soluble muscle proteins. By contrast, mice in which either the MAFbx- or MuRF-1-encoding gene has been deleted become partially resistant to atrophy induced by denervation, highlighting the crucial role of these two E3s in the process of muscle wasting. Finally, mice with altered control of the NF&#x003ba;B pathway demonstrate the key function of this pathway in inducing muscle atrophy.</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Mouse models genetically modified for proteins involved in muscle wasting</p></caption><table frame="hsides" rules="groups"><thead><tr><td>Genetically modified mice</td><td>Effect on muscle (muscle wasting condition tested)</td><td>Selected references</td></tr></thead><tbody><tr><td><bold>KO MuRF-1</bold></td><td>Partial protection against atrophy (denervation)</td><td>[31]</td></tr><tr><td><bold>KO Atrogin-1/MAFbx</bold></td><td>Partial protection against atrophy (denervation)</td><td>[31]</td></tr><tr><td><bold>KO E2-14K</bold></td><td>Non-resistant to atrophy (fasting)</td><td>[74,114]</td></tr><tr><td><bold>KO UBR1</bold></td><td>Decreased muscle mass</td><td>[75]</td></tr><tr><td><bold>Mdx</bold></td><td>Model for Duchenne muscular dystrophy: in these mice blockade of NF&#x003ba;B partially restores muscle function</td><td>[115]</td></tr><tr><td><bold>KI FoxO</bold></td><td>FoxO overexpressing mice: negative effect on skeletal muscle mass</td><td>[116]</td></tr><tr><td><bold>MIKK constitutively active IKK</bold></td><td>Severe atrophy resembling cachexia</td><td>[48]</td></tr><tr><td><bold>MISR non-degradable I&#x003ba;B</bold></td><td>Protection against atrophy (denervation, tumor)</td><td>[48]</td></tr></tbody></table></table-wrap></sec><sec><title>Assays for analysis of muscle wasting</title><p>In addition to the measurement of muscle mass after isolation of specific muscles from model animals, protein breakdown in incubated muscle is often quantified by the release of tyrosine, which is neither synthesized nor metabolized in skeletal muscle [<xref ref-type="bibr" rid="B76">76</xref>]. Furthermore, release of 3-methylhistidine, a modified amino acid found in actin and myosin that can be neither reincorporated into protein nor metabolized, can also be measured [<xref ref-type="bibr" rid="B77">77</xref>,<xref ref-type="bibr" rid="B78">78</xref>].</p></sec></sec><sec><title>Potential targets and drugs for muscle wasting therapy</title><p>As summarized in the section on <italic>Roles of the UPS in muscle wasting</italic> and figure <xref ref-type="fig" rid="F1">1</xref>, there are several levels of possible therapeutic intervention to limit muscle wasting. The first level is to modulate the expression or activity of circulating factors that either promote muscle hypertrophy (such as insulin or IGF-1) [<xref ref-type="bibr" rid="B79">79</xref>], inhibit muscle growth (such as myostatin) [<xref ref-type="bibr" rid="B58">58</xref>], or induce the UPS and/or NF&#x003ba;B (such as the cytokines TNF&#x003b1; or IL6, the secreted glycoprotein PIF, or oxidative stress) [<xref ref-type="bibr" rid="B5">5</xref>]. The second level involves targeting intracellular effectors of muscle wasting, such as the transcription factor FoxO or the NF&#x003ba;B pathway. Finally, a third level of possible therapeutic intervention is direct inhibition of the UPS.</p><fig position="float" id="F1"><label>Figure 1</label><caption><p><bold>Potential therapeutic targets in muscle wasting</bold>. The figure illustrates possible therapeutic targets in muscle wasting, including circulating factors, intracellular effectors and components of the ubiquitin proteasome system (UPS).</p></caption><graphic xlink:href="1471-2091-8-S1-S7-1"/></fig><p>As the exploration of these different possibilities is currently underway, only partial and limited information is presently available. To date, most compounds presently tested on animal models or in clinic for their ability to limit muscle wasting are commercially available chemicals, and many of them have been identified through empirical approaches aimed at treating cachexia [<xref ref-type="bibr" rid="B80">80</xref>]. Among those, EPA (eicosapentaenoic acid), which has been shown to down-regulate the increase in UPS activity seen in cachexia [<xref ref-type="bibr" rid="B81">81</xref>], and thalidomide, which inhibits production of TNF&#x003b1; by increasing the rate of degradation of its mRNA [<xref ref-type="bibr" rid="B82">82</xref>], have demonstrated a degree of efficacy [<xref ref-type="bibr" rid="B80">80</xref>,<xref ref-type="bibr" rid="B83">83</xref>,<xref ref-type="bibr" rid="B84">84</xref>].</p><p>Other inhibitors of TNF&#x003b1; expression represent attractive therapeutic strategies against cachexia. Although the xanthine derivative pentoxifylline [<xref ref-type="bibr" rid="B85">85</xref>] can suppress cachexia-induced activation of the UPS in rats [<xref ref-type="bibr" rid="B86">86</xref>], its effects in clinical trials have been uncertain [<xref ref-type="bibr" rid="B87">87</xref>]. However, another xanthine derivative, torbafylline (HWA 448), showed encouraging properties in a study on animal models, since it appeared more potent in preventing muscle wasting than pentoxifylline [<xref ref-type="bibr" rid="B88">88</xref>].</p><p>Several studies have analyzed the potential effect on muscle wasting of beta2 agonists such as clenbuterol [<xref ref-type="bibr" rid="B89">89</xref>], fenoterol [<xref ref-type="bibr" rid="B90">90</xref>] and formoterol [<xref ref-type="bibr" rid="B91">91</xref>]. These anabolic drugs appear effective against atrophy, mostly by counteracting activation of the UPS. Though the potential use of clenbuterol to treat muscle wasting appears limited since it has deleterious side effects in humans (particularly tachycardia and hypokalemia [<xref ref-type="bibr" rid="B92">92</xref>]), formoterol is already in use in human therapy (against chronic obstructive pulmonary disease) and thus appears to be an interesting candidate for human trials.</p><p>Due to the prominent role of NF&#x003ba;B in cachexia, drugs inhibiting the activation of this transcription factor have also been tested in various settings. Active molecules include HMB (&#x003b2;-hydroxy-&#x003b2;-methylbutyrate, a leucine metabolite) [<xref ref-type="bibr" rid="B80">80</xref>], ibuprofen [<xref ref-type="bibr" rid="B80">80</xref>] and resveratrol, the latter of which appears to be the most promising drug candidate for clinical use against muscle wasting [<xref ref-type="bibr" rid="B84">84</xref>,<xref ref-type="bibr" rid="B93">93</xref>].</p><p>Since the proteasome is a central component in muscle wasting, it represents an attractive target despite its pleiotropic functions. Indeed, many studies in animals have demonstrated that proteasome inhibitors are efficient at blocking muscle wasting [<xref ref-type="bibr" rid="B6">6</xref>,<xref ref-type="bibr" rid="B94">94</xref>]; however, no report on their effect on muscle wasting in humans has yet been published. The recent success of Millennium Pharmaceuticals with the proteasome inhibitor bortezomib (PS-341, Velcade&#x000ae;) for treatment of multiple myeloma [<xref ref-type="bibr" rid="B95">95</xref>] prompted many biotech or pharmaceutical companies to develop new molecules targeting the proteasome, including Nereus (NPI-0052), Proteolix (PR-171), Santhera and ALSTDF. Although muscle wasting is not the primary interest of these companies, these efforts could help to produce new compounds with interesting anti-atrophying properties in the future.</p><p>Finally, it is important to highlight that, when possible, muscular exercise is an efficient method of limiting disuse atrophy since, as shown by analyses in humans, it negatively influences the signaling pathways activated in muscle wasting, leading in particular to down-regulation of the E3s MAFbx and MuRF-1 [<xref ref-type="bibr" rid="B96">96</xref>].</p></sec><sec><title>New frontiers in drug discovery</title><p>Knowledge of the molecular mechanisms responsible for muscle wasting, as summarized in figure <xref ref-type="fig" rid="F1">1</xref>, has been acquired relatively recently and much remains to be understood before a more accurate description of this process is obtained. For example, the contribution of the AP-1 transcription factors to muscle wasting [<xref ref-type="bibr" rid="B97">97</xref>], or of the p38 MAP kinase to activation of MAFbx [<xref ref-type="bibr" rid="B98">98</xref>], remains to be clarified. In addition, future studies will certainly characterize novel factors involved in atrophy and provide a better evaluation of the therapeutic potential of activating or inhibiting the many pathways controlling muscle wasting. Nevertheless, as several levels of therapeutic intervention have been identified and drug candidates are currently being tested, it is most likely that efficient drugs against muscle wasting will be soon available. However, the many problems of bioavailability and of specific targeting of muscle tissues remain to be solved in most cases.</p><p>A clear limitation in the current attempts to reduce muscle wasting is that the targeted molecules are not muscle-specific; meaning that alteration of their expression or activity is bound to induce side effects that could worsen the clinical status of the patient. A combination of drugs displaying synergistic effects, as shown recently for pentoxifylline and formoterol [<xref ref-type="bibr" rid="B55">55</xref>], could help to improve treatment since this strategy could allow use of sub-therapeutic doses of each drug, decreasing the possibility of harmful side effects.</p><p>Clearly, an alternative goal is to develop compounds that will target specific factors that are key for muscle wasting and that have no general functions outside muscle. In this respect, the E3s specifically induced during muscle wasting, such as the N-end rule E3s or MuRF-1, are extremely attractive candidates. However, as illustrated in the Mdm2/p53 pathway (see [<xref ref-type="bibr" rid="B99">99</xref>] for review), the best approach to obtain specific and efficient inhibitors of E3s is to aim to disrupt the interaction of the E3 with its substrate(s). This requires substantial information on the nature of the relevant substrates of the E3 and on the structure of the E3&#x02013;substrate pair to be targeted. As such information is presently not available for the E3s involved in muscle wasting, important goals for the future are to identify their substrates and to define the structural basis of their interaction with these substrates.</p></sec><sec><title>List of abbreviations</title><p>Akt = serine/threonine protein kinase; FoxO = forkhead box O; GSK3 = glycogen synthase kinase 3; IGF-1 = insulin-like growth factor 1; KI = knockin; KO = knockout; MAFbx = muscle atrophy F-box; MAP kinase = mitogen-activated protein kinase; mTOR = mammalian target of rapamycin; MuRF1 = muscle RING finger 1; NF&#x003ba;B = nuclear factor kappa B; PI3K = phosphatidylinositol 3-kinase; PIF = proteolysis inducing factor; SCF = SKP1&#x02013;cullin&#x02013;F-box protein; SRF = serum response factor; TGF&#x003b2; = transforming growth factor beta; TNF&#x003b1; = tumor necrosis factor alpha; Ub = ubiquitin; UBD = ubiquitin binding domain; UPS = ubiquitin proteasome system.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Publication history</title><p>Republished from Current BioData's Targeted Proteins database (TPdb; <ext-link ext-link-type="uri" xlink:href="http://www.targetedproteinsdb.com"/>).</p></sec></body><back><ack><sec><title>Acknowledgements</title><p>We thank Dr. S.H. Lecker for critical reading of this manuscript. We also thank the members of our group for their help and suggestions. Our work on the roles of the UPS in muscle was supported by grants from the Association Fran&#x000e7;aise contre les Myopathies (AFM). DN and CD were supported by an AFM and a FRM (Fondation pour la Recherche M&#x000e9;dicale) fellowship, respectively.</p><p>This article has been published as part of <italic>BMC Biochemistry</italic> Volume 8 Supplement 1, 2007: Ubiquitin-Proteasome System in Disease Part 1. The full contents of the supplement are available online at <ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2091/8?issue=S1"/>.</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kandarian</surname><given-names>SC</given-names></name><name><surname>Jackman</surname><given-names>RW</given-names></name></person-group><article-title>Intracellular signaling during skeletal muscle atrophy</article-title><source>Muscle Nerve</source><year>2006</year><volume>33</volume><fpage>155</fpage><lpage>165</lpage><pub-id pub-id-type="pmid">16228971</pub-id><pub-id pub-id-type="doi">10.1002/mus.20442</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bechet</surname><given-names>D</given-names></name><name><surname>Tassa</surname><given-names>A</given-names></name><name><surname>Taillandier</surname><given-names>D</given-names></name><name><surname>Combaret</surname><given-names>L</given-names></name><name><surname>Attaix</surname><given-names>D</given-names></name></person-group><article-title>Lysosomal proteolysis in skeletal muscle</article-title><source>Int J Biochem Cell Biol</source><year>2005</year><volume>37</volume><fpage>2098</fpage><lpage>2114</lpage><pub-id pub-id-type="pmid">16125113</pub-id><pub-id pub-id-type="doi">10.1016/j.biocel.2005.02.029</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mitch</surname><given-names>WE</given-names></name><name><surname>Goldberg</surname><given-names>AL</given-names></name></person-group><article-title>Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway</article-title><source>N Engl J Med</source><year>1996</year><volume>335</volume><fpage>1897</fpage><lpage>1905</lpage><pub-id pub-id-type="pmid">8948566</pub-id><pub-id pub-id-type="doi">10.1056/NEJM199612193352507</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Attaix</surname><given-names>D</given-names></name><name><surname>Aurousseau</surname><given-names>E</given-names></name><name><surname>Combaret</surname><given-names>L</given-names></name><name><surname>Kee</surname><given-names>A</given-names></name><name><surname>Larbaud</surname><given-names>D</given-names></name><name><surname>Ralliere</surname><given-names>C</given-names></name><name><surname>Souweine</surname><given-names>B</given-names></name><name><surname>Taillandier</surname><given-names>D</given-names></name><name><surname>Tilignac</surname><given-names>T</given-names></name></person-group><article-title>Ubiquitin-proteasome-dependent proteolysis in skeletal muscle</article-title><source>Reprod Nutr Dev</source><year>1998</year><volume>38</volume><fpage>153</fpage><lpage>165</lpage><pub-id pub-id-type="pmid">9638789</pub-id><pub-id pub-id-type="doi">10.1051/rnd:19980202</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tisdale</surname><given-names>MJ</given-names></name></person-group><article-title>The ubiquitin-proteasome pathway as a therapeutic target for muscle wasting</article-title><source>J Support Oncol</source><year>2005</year><volume>3</volume><fpage>209</fpage><lpage>217</lpage><pub-id pub-id-type="pmid">15915823</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Attaix</surname><given-names>D</given-names></name><name><surname>Ventadour</surname><given-names>S</given-names></name><name><surname>Codran</surname><given-names>A</given-names></name><name><surname>Bechet</surname><given-names>D</given-names></name><name><surname>Taillandier</surname><given-names>D</given-names></name><name><surname>Combaret</surname><given-names>L</given-names></name></person-group><article-title>The ubiquitin-proteasome system and skeletal muscle wasting</article-title><source>Essays Biochem</source><year>2005</year><volume>41</volume><fpage>173</fpage><lpage>186</lpage><pub-id pub-id-type="pmid">16250905</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morley</surname><given-names>JE</given-names></name><name><surname>Thomas</surname><given-names>DR</given-names></name><name><surname>Wilson</surname><given-names>MM</given-names></name></person-group><article-title>Cachexia: pathophysiology and clinical relevance</article-title><source>Am J Clin Nutr</source><year>2006</year><volume>83</volume><fpage>735</fpage><lpage>743</lpage><pub-id pub-id-type="pmid">16600922</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wing</surname><given-names>SS</given-names></name></person-group><article-title>Control of ubiquitination in skeletal muscle wasting</article-title><source>Int J Biochem Cell Biol</source><year>2005</year><volume>37</volume><fpage>2075</fpage><lpage>2087</lpage><pub-id pub-id-type="pmid">16125111</pub-id><pub-id pub-id-type="doi">10.1016/j.biocel.2004.11.011</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Glass</surname><given-names>DJ</given-names></name></person-group><article-title>Skeletal muscle hypertrophy and atrophy signaling pathways</article-title><source>Int J Biochem Cell Biol</source><year>2005</year><volume>37</volume><fpage>1974</fpage><lpage>1984</lpage><pub-id pub-id-type="pmid">16087388</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lecker</surname><given-names>SH</given-names></name><name><surname>Goldberg</surname><given-names>AL</given-names></name><name><surname>Mitch</surname><given-names>WE</given-names></name></person-group><article-title>Protein degradation by the ubiquitin-proteasome pathway in normal and disease States</article-title><source>J Am Soc Nephrol</source><year>2006</year><volume>17</volume><fpage>1807</fpage><lpage>1819</lpage><pub-id pub-id-type="pmid">16738015</pub-id><pub-id pub-id-type="doi">10.1681/ASN.2006010083</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stein</surname><given-names>TP</given-names></name><name><surname>Bolster</surname><given-names>DR</given-names></name></person-group><article-title>Insights into muscle atrophy and recovery pathway based on genetic models</article-title><source>Curr Opin Clin Nutr Metab Care</source><year>2006</year><volume>9</volume><fpage>395</fpage><lpage>402</lpage><pub-id pub-id-type="pmid">16778568</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Attaix</surname><given-names>D</given-names></name><name><surname>Taillandier</surname><given-names>D</given-names></name><name><surname>Temparis</surname><given-names>S</given-names></name><name><surname>Larbaud</surname><given-names>D</given-names></name><name><surname>Aurousseau</surname><given-names>E</given-names></name><name><surname>Combaret</surname><given-names>L</given-names></name><name><surname>Voisin</surname><given-names>L</given-names></name></person-group><article-title>Regulation of ATP-ubiquitin-dependent proteolysis in muscle wasting</article-title><source>Reprod Nutr Dev</source><year>1994</year><volume>34</volume><fpage>583</fpage><lpage>597</lpage><pub-id pub-id-type="pmid">7840873</pub-id><pub-id pub-id-type="doi">10.1051/rnd:19940605</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Etlinger</surname><given-names>J</given-names></name><name><surname>Goldberg</surname><given-names>AL</given-names></name></person-group><article-title>A soluble, ATP-dependent proteolytic system responsible for the degradation of abnormal proteins in reticulocytes</article-title><source>Proc Natl Acad Sci USA</source><year>1977</year><volume>74</volume><fpage>54</fpage><lpage>58</lpage><pub-id pub-id-type="pmid">264694</pub-id><pub-id pub-id-type="doi">10.1073/pnas.74.1.54</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ciechanover</surname><given-names>A</given-names></name><name><surname>Elias</surname><given-names>S</given-names></name><name><surname>Heller</surname><given-names>H</given-names></name><name><surname>Ferber</surname><given-names>S</given-names></name><name><surname>Hershko</surname><given-names>A</given-names></name></person-group><article-title>Characterization of the heat-stable polypeptide of the ATP-dependent proteolytic system from reticulocytes</article-title><source>J Biol Chem</source><year>1980</year><volume>255</volume><fpage>7525</fpage><lpage>7528</lpage><pub-id pub-id-type="pmid">6249802</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ganoth</surname><given-names>D</given-names></name><name><surname>Leshinsky</surname><given-names>E</given-names></name><name><surname>Eytan</surname><given-names>E</given-names></name><name><surname>Hershko</surname><given-names>A</given-names></name></person-group><article-title>A multicomponent system that degrades proteins conjugated to ubiquitin. Resolution of factors and evidence for ATP-dependent complex formation</article-title><source>J Biol Chem</source><year>1988</year><volume>263</volume><fpage>12412</fpage><lpage>12419</lpage><pub-id pub-id-type="pmid">2842333</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ciechanover</surname><given-names>A</given-names></name></person-group><article-title>Proteolysis: from the lysosome to ubiquitin and the proteasome</article-title><source>Nat Rev Mol Cell Biol</source><year>2005</year><volume>6</volume><fpage>79</fpage><lpage>87</lpage><pub-id pub-id-type="pmid">15688069</pub-id><pub-id pub-id-type="doi">10.1038/nrm1552</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tawa</surname><given-names>NE</given-names></name><name><surname>Odessey</surname><given-names>R</given-names></name><name><surname>Goldberg</surname><given-names>AL</given-names></name></person-group><article-title>Inhibitors of the proteasome reduce the accelerated proteolysis in atrophying rat skeletal muscles</article-title><source>J Clin Invest</source><year>1997</year><volume>100</volume><fpage>197</fpage><lpage>203</lpage><pub-id pub-id-type="pmid">9202072</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hershko</surname><given-names>A</given-names></name><name><surname>Ciechanover</surname><given-names>A</given-names></name></person-group><article-title>The ubiquitin system</article-title><source>Annu Rev Biochem</source><year>1998</year><volume>67</volume><fpage>425</fpage><lpage>479</lpage><pub-id pub-id-type="pmid">9759494</pub-id><pub-id pub-id-type="doi">10.1146/annurev.biochem.67.1.425</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schulman</surname><given-names>BA</given-names></name><name><surname>Carrano</surname><given-names>AC</given-names></name><name><surname>Jeffrey</surname><given-names>PD</given-names></name><name><surname>Bowen</surname><given-names>Z</given-names></name><name><surname>Kinnucan</surname><given-names>ER</given-names></name><name><surname>Finnin</surname><given-names>MS</given-names></name><name><surname>Elledge</surname><given-names>SJ</given-names></name><name><surname>Harper</surname><given-names>JW</given-names></name><name><surname>Pagano</surname><given-names>M</given-names></name><name><surname>Pavletich</surname><given-names>NP</given-names></name></person-group><article-title>Insights into SCF ubiquitin ligases from the structure of the Skp1-Skp2 complex</article-title><source>Nature</source><year>2000</year><volume>408</volume><fpage>381</fpage><lpage>386</lpage><pub-id pub-id-type="pmid">11099048</pub-id><pub-id pub-id-type="doi">10.1038/35042620</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Robinson</surname><given-names>PA</given-names></name></person-group><article-title>Ubiquitin-protein ligases - novel therapeutic targets?</article-title><source>Curr Protein Pept Sci</source><year>2004</year><volume>5</volume><fpage>163</fpage><lpage>176</lpage><pub-id pub-id-type="pmid">15180521</pub-id><pub-id pub-id-type="doi">10.2174/1389203043379800</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Voges</surname><given-names>D</given-names></name><name><surname>Zwickl</surname><given-names>P</given-names></name><name><surname>Baumeister</surname><given-names>W</given-names></name></person-group><article-title>The 26S proteasome: a molecular machine designed for controlled proteolysis</article-title><source>Annu Rev Biochem</source><year>1999</year><volume>68</volume><fpage>1015</fpage><lpage>1068</lpage><pub-id pub-id-type="pmid">10872471</pub-id><pub-id pub-id-type="doi">10.1146/annurev.biochem.68.1.1015</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rechsteiner</surname><given-names>M</given-names></name><name><surname>Hill</surname><given-names>CP</given-names></name></person-group><article-title>Mobilizing the proteolytic machine: cell biological roles of proteasome activators and inhibitors</article-title><source>Trends Cell Biol</source><year>2005</year><volume>15</volume><fpage>27</fpage><lpage>33</lpage><pub-id pub-id-type="pmid">15653075</pub-id><pub-id pub-id-type="doi">10.1016/j.tcb.2004.11.003</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Price</surname><given-names>SR</given-names></name></person-group><article-title>Increased transcription of ubiquitin-proteasome system components: molecular responses associated with muscle atrophy</article-title><source>Int J Biochem Cell Biol</source><year>2003</year><volume>35</volume><fpage>617</fpage><lpage>628</lpage><pub-id pub-id-type="pmid">12672454</pub-id><pub-id pub-id-type="doi">10.1016/S1357-2725(02)00385-0</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lecker</surname><given-names>SH</given-names></name></person-group><article-title>Ubiquitin-protein ligases in muscle wasting: multiple parallel pathways?</article-title><source>Curr Opin Clin Nutr Metab Care</source><year>2003</year><volume>6</volume><fpage>271</fpage><lpage>275</lpage><pub-id pub-id-type="pmid">12690258</pub-id><pub-id pub-id-type="doi">10.1097/00075197-200305000-00001</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Combaret</surname><given-names>L</given-names></name><name><surname>Adegoke</surname><given-names>OA</given-names></name><name><surname>Bedard</surname><given-names>N</given-names></name><name><surname>Baracos</surname><given-names>V</given-names></name><name><surname>Attaix</surname><given-names>D</given-names></name><name><surname>Wing</surname><given-names>SS</given-names></name></person-group><article-title>USP19 is a ubiquitin-specific protease regulated in rat skeletal muscle during catabolic states</article-title><source>Am J Physiol Endocrinol Metab</source><year>2005</year><volume>288</volume><fpage>E693</fpage><lpage>700</lpage><pub-id pub-id-type="pmid">15562254</pub-id><pub-id pub-id-type="doi">10.1152/ajpendo.00281.2004</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Solomon</surname><given-names>V</given-names></name><name><surname>Baracos</surname><given-names>V</given-names></name><name><surname>Sarraf</surname><given-names>P</given-names></name><name><surname>Goldberg</surname><given-names>AL</given-names></name></person-group><article-title>Rates of ubiquitin conjugation increase when muscles atrophy, largely through activation of the N-end rule pathway</article-title><source>Proc Natl Acad Sci U S A</source><year>1998</year><volume>95</volume><fpage>12602</fpage><lpage>12607</lpage><pub-id pub-id-type="pmid">9770532</pub-id><pub-id pub-id-type="doi">10.1073/pnas.95.21.12602</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kwak</surname><given-names>KS</given-names></name><name><surname>Zhou</surname><given-names>X</given-names></name><name><surname>Solomon</surname><given-names>V</given-names></name><name><surname>Baracos</surname><given-names>VE</given-names></name><name><surname>Davis</surname><given-names>J</given-names></name><name><surname>Bannon</surname><given-names>AW</given-names></name><name><surname>Boyle</surname><given-names>WJ</given-names></name><name><surname>Lacey</surname><given-names>DL</given-names></name><name><surname>Han</surname><given-names>HQ</given-names></name></person-group><article-title>Regulation of protein catabolism by muscle-specific and cytokine-inducible ubiquitin ligase E3{alpha}-II during cancer cachexia</article-title><source>Cancer Res</source><year>2004</year><volume>64</volume><fpage>8193</fpage><lpage>8198</lpage><pub-id pub-id-type="pmid">15548684</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-2102</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Varshavsky</surname><given-names>A</given-names></name><name><surname>Turner</surname><given-names>G</given-names></name><name><surname>Du</surname><given-names>F</given-names></name><name><surname>Xie</surname><given-names>Y</given-names></name></person-group><article-title>The ubiquitin system and the N-end rule pathway</article-title><source>Biol Chem</source><year>2000</year><volume>381</volume><fpage>779</fpage><lpage>789</lpage><pub-id pub-id-type="pmid">11076011</pub-id><pub-id pub-id-type="doi">10.1515/BC.2000.101</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tasaki</surname><given-names>T</given-names></name><name><surname>Mulder</surname><given-names>LC</given-names></name><name><surname>Iwamatsu</surname><given-names>A</given-names></name><name><surname>Lee</surname><given-names>MJ</given-names></name><name><surname>Davydov</surname><given-names>IV</given-names></name><name><surname>Varshavsky</surname><given-names>A</given-names></name><name><surname>Muesing</surname><given-names>M</given-names></name><name><surname>Kwon</surname><given-names>YT</given-names></name></person-group><article-title>A family of mammalian E3 ubiquitin ligases that contain the UBR Box Motif and recognize N-degrons</article-title><source>Mol Cell Biol</source><year>2005</year><volume>25</volume><fpage>7120</fpage><lpage>7136</lpage><pub-id pub-id-type="pmid">16055722</pub-id><pub-id pub-id-type="doi">10.1128/MCB.25.16.7120-7136.2005</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gomes</surname><given-names>MD</given-names></name><name><surname>Lecker</surname><given-names>SH</given-names></name><name><surname>Jagoe</surname><given-names>RT</given-names></name><name><surname>Navon</surname><given-names>A</given-names></name><name><surname>Goldberg</surname><given-names>AL</given-names></name></person-group><article-title>Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy</article-title><source>Proc Natl Acad Sci U S A</source><year>2001</year><volume>98</volume><fpage>14440</fpage><lpage>14445</lpage><pub-id pub-id-type="pmid">11717410</pub-id><pub-id pub-id-type="doi">10.1073/pnas.251541198</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bodine</surname><given-names>SC</given-names></name><name><surname>Latres</surname><given-names>E</given-names></name><name><surname>Baumhueter</surname><given-names>S</given-names></name><name><surname>Lai</surname><given-names>VK</given-names></name><name><surname>Nunez</surname><given-names>L</given-names></name><name><surname>Clarke</surname><given-names>BA</given-names></name><name><surname>Poueymirou</surname><given-names>WT</given-names></name><name><surname>Panaro</surname><given-names>FJ</given-names></name><name><surname>Na</surname><given-names>E</given-names></name><name><surname>Dharmarajan</surname><given-names>K</given-names></name><name><surname>Pan</surname><given-names>ZQ</given-names></name><name><surname>Valenzuela</surname><given-names>DM</given-names></name><name><surname>DeChiara</surname><given-names>TM</given-names></name><name><surname>Stitt</surname><given-names>TN</given-names></name><name><surname>Yancopoulos</surname><given-names>GD</given-names></name><name><surname>Glass</surname><given-names>DJ</given-names></name></person-group><article-title>Identification of ubiquitin ligases required for skeletal muscle atrophy</article-title><source>Science</source><year>2001</year><volume>294</volume><fpage>1704</fpage><lpage>1708</lpage><pub-id pub-id-type="pmid">11679633</pub-id><pub-id pub-id-type="doi">10.1126/science.1065874</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>HH</given-names></name><name><surname>Kedar</surname><given-names>V</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>McDonough</surname><given-names>H</given-names></name><name><surname>Arya</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>DZ</given-names></name><name><surname>Patterson</surname><given-names>C</given-names></name></person-group><article-title>Atrogin-1/muscle atrophy F-box inhibits calcineurin-dependent cardiac hypertrophy by participating in an SCF ubiquitin ligase complex</article-title><source>J Clin Invest</source><year>2004</year><volume>114</volume><fpage>1058</fpage><lpage>1071</lpage><pub-id pub-id-type="pmid">15489953</pub-id><pub-id pub-id-type="doi">10.1172/JCI200422220</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Witt</surname><given-names>SH</given-names></name><name><surname>Granzier</surname><given-names>H</given-names></name><name><surname>Witt</surname><given-names>CC</given-names></name><name><surname>Labeit</surname><given-names>S</given-names></name></person-group><article-title>MURF-1 and MURF-2 target a specific subset of myofibrillar proteins redundantly: towards understanding MURF-dependent muscle ubiquitination</article-title><source>J Mol Biol</source><year>2005</year><volume>350</volume><fpage>713</fpage><lpage>722</lpage><pub-id pub-id-type="pmid">15967462</pub-id><pub-id pub-id-type="doi">10.1016/j.jmb.2005.05.021</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Solomon</surname><given-names>V</given-names></name><name><surname>Goldberg</surname><given-names>AL</given-names></name></person-group><article-title>Importance of the ATP-ubiquitin-proteasome pathway in the degradation of soluble and myofibrillar proteins in rabbit muscle extracts</article-title><source>J Biol Chem</source><year>1996</year><volume>271</volume><fpage>26690</fpage><lpage>26697</lpage><pub-id pub-id-type="pmid">8900146</pub-id><pub-id pub-id-type="doi">10.1074/jbc.271.41.25240</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bartoli</surname><given-names>M</given-names></name><name><surname>Richard</surname><given-names>I</given-names></name></person-group><article-title>Calpains in muscle wasting</article-title><source>Int J Biochem Cell Biol</source><year>2005</year><volume>37</volume><fpage>2115</fpage><lpage>2133</lpage><pub-id pub-id-type="pmid">16125114</pub-id><pub-id pub-id-type="doi">10.1016/j.biocel.2004.12.012</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Costelli</surname><given-names>P</given-names></name><name><surname>Reffo</surname><given-names>P</given-names></name><name><surname>Penna</surname><given-names>F</given-names></name><name><surname>Autelli</surname><given-names>R</given-names></name><name><surname>Bonelli</surname><given-names>G</given-names></name><name><surname>Baccino</surname><given-names>FM</given-names></name></person-group><article-title>Ca(2+)-dependent proteolysis in muscle wasting</article-title><source>Int J Biochem Cell Biol</source><year>2005</year><volume>37</volume><fpage>2134</fpage><lpage>2146</lpage><pub-id pub-id-type="pmid">15893952</pub-id><pub-id pub-id-type="doi">10.1016/j.biocel.2005.03.010</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Miereles</surname><given-names>C</given-names></name><name><surname>Bailey</surname><given-names>JL</given-names></name><name><surname>Debigare</surname><given-names>R</given-names></name><name><surname>Zheng</surname><given-names>B</given-names></name><name><surname>Price</surname><given-names>SR</given-names></name><name><surname>Mitch</surname><given-names>WE</given-names></name></person-group><article-title>Activation of caspase-3 is an initial step triggering accelerated muscle proteolysis in catabolic conditions</article-title><source>J Clin Invest</source><year>2004</year><volume>113</volume><fpage>115</fpage><lpage>123</lpage><pub-id pub-id-type="pmid">14702115</pub-id><pub-id pub-id-type="doi">10.1172/JCI200418330</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Deval</surname><given-names>C</given-names></name><name><surname>Mordier</surname><given-names>S</given-names></name><name><surname>Obled</surname><given-names>C</given-names></name><name><surname>Bechet</surname><given-names>D</given-names></name><name><surname>Combaret</surname><given-names>L</given-names></name><name><surname>Attaix</surname><given-names>D</given-names></name><name><surname>Ferrara</surname><given-names>M</given-names></name></person-group><article-title>Identification of cathepsin L as a differentially expressed message associated with skeletal muscle wasting</article-title><source>Biochem J</source><year>2001</year><volume>360</volume><fpage>143</fpage><lpage>150</lpage><pub-id pub-id-type="pmid">11696001</pub-id><pub-id pub-id-type="doi">10.1042/0264-6021:3600143</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rao</surname><given-names>H</given-names></name><name><surname>Uhlmann</surname><given-names>F</given-names></name><name><surname>Nasmyth</surname><given-names>K</given-names></name><name><surname>Varshavsky</surname><given-names>A</given-names></name></person-group><article-title>Degradation of a cohesin subunit by the N-end rule pathway is essential for chromosome stability</article-title><source>Nature</source><year>2001</year><volume>410</volume><fpage>955</fpage><lpage>959</lpage><pub-id pub-id-type="pmid">11309624</pub-id><pub-id pub-id-type="doi">10.1038/35073627</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gotthardt</surname><given-names>M</given-names></name><name><surname>Hammer</surname><given-names>RE</given-names></name><name><surname>Hubner</surname><given-names>N</given-names></name><name><surname>Monti</surname><given-names>J</given-names></name><name><surname>Witt</surname><given-names>CC</given-names></name><name><surname>McNabb</surname><given-names>M</given-names></name><name><surname>Richardson</surname><given-names>JA</given-names></name><name><surname>Granzier</surname><given-names>H</given-names></name><name><surname>Labeit</surname><given-names>S</given-names></name><name><surname>Herz</surname><given-names>J</given-names></name></person-group><article-title>Conditional expression of mutant M-line titins results in cardiomyopathy with altered sarcomere structure</article-title><source>J Biol Chem</source><year>2003</year><volume>278</volume><fpage>6059</fpage><lpage>6065</lpage><pub-id pub-id-type="pmid">12464612</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M211723200</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Miller</surname><given-names>G</given-names></name><name><surname>Musa</surname><given-names>H</given-names></name><name><surname>Gautel</surname><given-names>M</given-names></name><name><surname>Peckham</surname><given-names>M</given-names></name></person-group><article-title>A targeted deletion of the C-terminal end of titin, including the titin kinase domain, impairs myofibrillogenesis</article-title><source>J Cell Sci</source><year>2003</year><volume>116</volume><fpage>4811</fpage><lpage>4819</lpage><pub-id pub-id-type="pmid">14600266</pub-id><pub-id pub-id-type="doi">10.1242/jcs.00768</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grater</surname><given-names>F</given-names></name><name><surname>Shen</surname><given-names>J</given-names></name><name><surname>Jiang</surname><given-names>H</given-names></name><name><surname>Gautel</surname><given-names>M</given-names></name><name><surname>Grubmuller</surname><given-names>H</given-names></name></person-group><article-title>Mechanically induced titin kinase activation studied by force-probe molecular dynamics simulations</article-title><source>Biophys J</source><year>2005</year><volume>88</volume><fpage>790</fpage><lpage>804</lpage><pub-id pub-id-type="pmid">15531631</pub-id><pub-id pub-id-type="doi">10.1529/biophysj.104.052423</pub-id></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hicke</surname><given-names>L</given-names></name><name><surname>Schubert</surname><given-names>HL</given-names></name><name><surname>Hill</surname><given-names>CP</given-names></name></person-group><article-title>Ubiquitin-binding domains</article-title><source>Nat Rev Mol Cell Biol</source><year>2005</year><volume>6</volume><fpage>610</fpage><lpage>621</lpage><pub-id pub-id-type="pmid">16064137</pub-id><pub-id pub-id-type="doi">10.1038/nrm1701</pub-id></citation></ref><ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lange</surname><given-names>S</given-names></name><name><surname>Xiang</surname><given-names>F</given-names></name><name><surname>Yakovenko</surname><given-names>A</given-names></name><name><surname>Vihola</surname><given-names>A</given-names></name><name><surname>Hackman</surname><given-names>P</given-names></name><name><surname>Rostkova</surname><given-names>E</given-names></name><name><surname>Kristensen</surname><given-names>J</given-names></name><name><surname>Brandmeier</surname><given-names>B</given-names></name><name><surname>Franzen</surname><given-names>G</given-names></name><name><surname>Hedberg</surname><given-names>B</given-names></name><name><surname>Gunnarsson</surname><given-names>LG</given-names></name><name><surname>Hughes</surname><given-names>SM</given-names></name><name><surname>Marchand</surname><given-names>S</given-names></name><name><surname>Sejersen</surname><given-names>T</given-names></name><name><surname>Richard</surname><given-names>I</given-names></name><name><surname>Edstrom</surname><given-names>L</given-names></name><name><surname>Ehler</surname><given-names>E</given-names></name><name><surname>Udd</surname><given-names>B</given-names></name><name><surname>Gautel</surname><given-names>M</given-names></name></person-group><article-title>The kinase domain of titin controls muscle gene expression and protein turnover</article-title><source>Science</source><year>2005</year><volume>308</volume><fpage>1599</fpage><lpage>1603</lpage><pub-id pub-id-type="pmid">15802564</pub-id><pub-id pub-id-type="doi">10.1126/science.1110463</pub-id></citation></ref><ref id="B45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Combaret</surname><given-names>L</given-names></name><name><surname>Taillandier</surname><given-names>D</given-names></name><name><surname>Dardevet</surname><given-names>D</given-names></name><name><surname>Bechet</surname><given-names>D</given-names></name><name><surname>Ralliere</surname><given-names>C</given-names></name><name><surname>Claustre</surname><given-names>A</given-names></name><name><surname>Grizard</surname><given-names>J</given-names></name><name><surname>Attaix</surname><given-names>D</given-names></name></person-group><article-title>Glucocorticoids regulate mRNA levels for subunits of the 19 S regulatory complex of the 26 S proteasome in fast-twitch skeletal muscles</article-title><source>Biochem J</source><year>2004</year><volume>378</volume><fpage>239</fpage><lpage>246</lpage><pub-id pub-id-type="pmid">14636157</pub-id><pub-id pub-id-type="doi">10.1042/BJ20031660</pub-id></citation></ref><ref id="B46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sandri</surname><given-names>M</given-names></name><name><surname>Sandri</surname><given-names>C</given-names></name><name><surname>Gilbert</surname><given-names>A</given-names></name><name><surname>Skurk</surname><given-names>C</given-names></name><name><surname>Calabria</surname><given-names>E</given-names></name><name><surname>Picard</surname><given-names>A</given-names></name><name><surname>Walsh</surname><given-names>K</given-names></name><name><surname>Schiaffino</surname><given-names>S</given-names></name><name><surname>Lecker</surname><given-names>SH</given-names></name><name><surname>Goldberg</surname><given-names>AL</given-names></name></person-group><article-title>Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy</article-title><source>Cell</source><year>2004</year><volume>117</volume><fpage>399</fpage><lpage>412</lpage><pub-id pub-id-type="pmid">15109499</pub-id><pub-id pub-id-type="doi">10.1016/S0092-8674(04)00400-3</pub-id></citation></ref><ref id="B47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stitt</surname><given-names>TN</given-names></name><name><surname>Drujan</surname><given-names>D</given-names></name><name><surname>Clarke</surname><given-names>BA</given-names></name><name><surname>Panaro</surname><given-names>F</given-names></name><name><surname>Timofeyva</surname><given-names>Y</given-names></name><name><surname>Kline</surname><given-names>WO</given-names></name><name><surname>Gonzalez</surname><given-names>M</given-names></name><name><surname>Yancopoulos</surname><given-names>GD</given-names></name><name><surname>Glass</surname><given-names>DJ</given-names></name></person-group><article-title>The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors</article-title><source>Mol Cell</source><year>2004</year><volume>14</volume><fpage>395</fpage><lpage>403</lpage><pub-id pub-id-type="pmid">15125842</pub-id><pub-id pub-id-type="doi">10.1016/S1097-2765(04)00211-4</pub-id></citation></ref><ref id="B48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>D</given-names></name><name><surname>Frantz</surname><given-names>JD</given-names></name><name><surname>Tawa</surname><given-names>NE</given-names><suffix>Jr</suffix></name><name><surname>Melendez</surname><given-names>PA</given-names></name><name><surname>Oh</surname><given-names>BC</given-names></name><name><surname>Lidov</surname><given-names>HG</given-names></name><name><surname>Hasselgren</surname><given-names>PO</given-names></name><name><surname>Frontera</surname><given-names>WR</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Glass</surname><given-names>DJ</given-names></name><name><surname>Shoelson</surname><given-names>SE</given-names></name></person-group><article-title>IKKbeta/NF-kappaB activation causes severe muscle wasting in mice</article-title><source>Cell</source><year>2004</year><volume>119</volume><fpage>285</fpage><lpage>298</lpage><pub-id pub-id-type="pmid">15479644</pub-id><pub-id pub-id-type="doi">10.1016/j.cell.2004.09.027</pub-id></citation></ref><ref id="B49"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rommel</surname><given-names>C</given-names></name><name><surname>Bodine</surname><given-names>SC</given-names></name><name><surname>Clarke</surname><given-names>BA</given-names></name><name><surname>Rossman</surname><given-names>R</given-names></name><name><surname>Nunez</surname><given-names>L</given-names></name><name><surname>Stitt</surname><given-names>TN</given-names></name><name><surname>Yancopoulos</surname><given-names>GD</given-names></name><name><surname>Glass</surname><given-names>DJ</given-names></name></person-group><article-title>Mediation of IGF-1-induced skeletal myotube hypertrophy by PI(3)K/Akt/mTOR and PI(3)K/Akt/GSK3 pathways</article-title><source>Nat Cell Biol</source><year>2001</year><volume>3</volume><fpage>1009</fpage><lpage>1013</lpage><pub-id pub-id-type="pmid">11715022</pub-id><pub-id pub-id-type="doi">10.1038/ncb1101-1009</pub-id></citation></ref><ref id="B50"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname><given-names>KM</given-names></name><name><surname>Gonzalez</surname><given-names>M</given-names></name><name><surname>Poueymirou</surname><given-names>WT</given-names></name><name><surname>Kline</surname><given-names>WO</given-names></name><name><surname>Na</surname><given-names>E</given-names></name><name><surname>Zlotchenko</surname><given-names>E</given-names></name><name><surname>Stitt</surname><given-names>TN</given-names></name><name><surname>Economides</surname><given-names>AN</given-names></name><name><surname>Yancopoulos</surname><given-names>GD</given-names></name><name><surname>Glass</surname><given-names>DJ</given-names></name></person-group><article-title>Conditional activation of akt in adult skeletal muscle induces rapid hypertrophy</article-title><source>Mol Cell Biol</source><year>2004</year><volume>24</volume><fpage>9295</fpage><lpage>9304</lpage><pub-id pub-id-type="pmid">15485899</pub-id><pub-id pub-id-type="doi">10.1128/MCB.24.21.9295-9304.2004</pub-id></citation></ref><ref id="B51"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sacheck</surname><given-names>JM</given-names></name><name><surname>Ohtsuka</surname><given-names>A</given-names></name><name><surname>McLary</surname><given-names>SC</given-names></name><name><surname>Goldberg</surname><given-names>AL</given-names></name></person-group><article-title>IGF-I stimulates muscle growth by suppressing protein breakdown and expression of atrophy-related ubiquitin ligases, atrogin-1 and MuRF1</article-title><source>Am J Physiol Endocrinol Metab</source><year>2004</year><volume>287</volume><fpage>E591</fpage><lpage>601</lpage><pub-id pub-id-type="pmid">15100091</pub-id><pub-id pub-id-type="doi">10.1152/ajpendo.00073.2004</pub-id></citation></ref><ref id="B52"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nader</surname><given-names>GA</given-names></name></person-group><article-title>Molecular determinants of skeletal muscle mass: getting the &#x0201c;AKT&#x0201d; together</article-title><source>Int J Biochem Cell Biol</source><year>2005</year><volume>37</volume><fpage>1985</fpage><lpage>1996</lpage><pub-id pub-id-type="pmid">16125108</pub-id><pub-id pub-id-type="doi">10.1016/j.biocel.2005.02.026</pub-id></citation></ref><ref id="B53"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>SW</given-names></name><name><surname>Dai</surname><given-names>G</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Du</surname><given-names>J</given-names></name><name><surname>Mitch</surname><given-names>WE</given-names></name></person-group><article-title>Regulation of muscle protein degradation: coordinated control of apoptotic and ubiquitin-proteasome systems by phosphatidylinositol 3 kinase</article-title><source>J Am Soc Nephrol</source><year>2004</year><volume>15</volume><fpage>1537</fpage><lpage>1545</lpage><pub-id pub-id-type="pmid">15153564</pub-id><pub-id pub-id-type="doi">10.1097/01.ASN.0000127211.86206.E1</pub-id></citation></ref><ref id="B54"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bailey</surname><given-names>JL</given-names></name><name><surname>Zheng</surname><given-names>B</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Price</surname><given-names>SR</given-names></name><name><surname>Mitch</surname><given-names>WE</given-names></name></person-group><article-title>Chronic kidney disease causes defects in signaling through the insulin receptor substrate/phosphatidylinositol 3-kinase/Akt pathway: implications for muscle atrophy</article-title><source>J Am Soc Nephrol</source><year>2006</year><volume>17</volume><fpage>1388</fpage><lpage>1394</lpage><pub-id pub-id-type="pmid">16611720</pub-id><pub-id pub-id-type="doi">10.1681/ASN.2004100842</pub-id></citation></ref><ref id="B55"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Costelli</surname><given-names>P</given-names></name><name><surname>Muscaritoli</surname><given-names>M</given-names></name><name><surname>Bossola</surname><given-names>M</given-names></name><name><surname>Penna</surname><given-names>F</given-names></name><name><surname>Reffo</surname><given-names>P</given-names></name><name><surname>Bonetto</surname><given-names>A</given-names></name><name><surname>Busquets</surname><given-names>S</given-names></name><name><surname>Bonelli</surname><given-names>G</given-names></name><name><surname>Lopez-Soriano</surname><given-names>FJ</given-names></name><name><surname>Doglietto</surname><given-names>GB</given-names></name><name><surname>Argiles</surname><given-names>JM</given-names></name><name><surname>Baccino</surname><given-names>FM</given-names></name><name><surname>Rossi Fanelli</surname><given-names>F</given-names></name></person-group><article-title>IGF-1 is down-regulated in experimental cancer cachexia</article-title><source>Am J Physiol Regul Integr Comp Physiol</source><year>2006</year><volume>291</volume><fpage>R674</fpage><lpage>683</lpage><pub-id pub-id-type="pmid">16614058</pub-id></citation></ref><ref id="B56"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Hu</surname><given-names>Z</given-names></name><name><surname>Hu</surname><given-names>J</given-names></name><name><surname>Du</surname><given-names>J</given-names></name><name><surname>Mitch</surname><given-names>WE</given-names></name></person-group><article-title>Insulin resistance accelerates muscle protein degradation: activation of the ubiquitin-proteasome pathway by defects in muscle cell signaling</article-title><source>Endocrinology</source><year>2006</year><volume>147</volume><fpage>4160</fpage><lpage>4168</lpage><pub-id pub-id-type="pmid">16777975</pub-id><pub-id pub-id-type="doi">10.1210/en.2006-0251</pub-id></citation></ref><ref id="B57"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McFarlane</surname><given-names>C</given-names></name><name><surname>Plummer</surname><given-names>E</given-names></name><name><surname>Thomas</surname><given-names>M</given-names></name><name><surname>Hennebry</surname><given-names>A</given-names></name><name><surname>Ashby</surname><given-names>M</given-names></name><name><surname>Ling</surname><given-names>N</given-names></name><name><surname>Smith</surname><given-names>H</given-names></name><name><surname>Sharma</surname><given-names>M</given-names></name><name><surname>Kambadur</surname><given-names>R</given-names></name></person-group><article-title>Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-kappaB-independent, FoxO1-dependent mechanism</article-title><source>J Cell Physiol</source><year>2006</year><volume>209</volume><fpage>501</fpage><lpage>514</lpage><pub-id pub-id-type="pmid">16883577</pub-id><pub-id pub-id-type="doi">10.1002/jcp.20757</pub-id></citation></ref><ref id="B58"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Joulia-Ekaza</surname><given-names>D</given-names></name><name><surname>Cabello</surname><given-names>G</given-names></name></person-group><article-title>Mysostatin regulation of muscle development: molecular basis, natural mutations, physiopathological aspects</article-title><source>Exp Cell Res</source><year>2006</year><volume>312</volume><fpage>2401</fpage><lpage>2414</lpage><pub-id pub-id-type="pmid">16793037</pub-id></citation></ref><ref id="B59"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Szewczyk</surname><given-names>NJ</given-names></name><name><surname>Jacobson</surname><given-names>LA</given-names></name></person-group><article-title>Signal-transduction networks and the regulation of muscle protein degradation</article-title><source>Int J Biochem Cell Biol</source><year>2005</year><volume>37</volume><fpage>1997</fpage><lpage>2011</lpage><pub-id pub-id-type="pmid">16125109</pub-id><pub-id pub-id-type="doi">10.1016/j.biocel.2005.02.020</pub-id></citation></ref><ref id="B60"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>ZJ</given-names></name></person-group><article-title>Ubiquitin signalling in the NF-kappaB pathway</article-title><source>Nat Cell Biol</source><year>2005</year><volume>7</volume><fpage>758</fpage><lpage>765</lpage><pub-id pub-id-type="pmid">16056267</pub-id><pub-id pub-id-type="doi">10.1038/ncb0805-758</pub-id></citation></ref><ref id="B61"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kawamura</surname><given-names>I</given-names></name><name><surname>Morishita</surname><given-names>R</given-names></name><name><surname>Tomita</surname><given-names>N</given-names></name><name><surname>Lacey</surname><given-names>E</given-names></name><name><surname>Aketa</surname><given-names>M</given-names></name><name><surname>Tsujimoto</surname><given-names>S</given-names></name><name><surname>Manda</surname><given-names>T</given-names></name><name><surname>Tomoi</surname><given-names>M</given-names></name><name><surname>Kida</surname><given-names>I</given-names></name><name><surname>Higaki</surname><given-names>J</given-names></name><name><surname>Kaneda</surname><given-names>Y</given-names></name><name><surname>Shimomura</surname><given-names>K</given-names></name><name><surname>Ogihara</surname><given-names>T</given-names></name></person-group><article-title>Intratumoral injection of oligonucleotides to the NF kappa B binding site inhibits cachexia in a mouse tumor model</article-title><source>Gene Ther</source><year>1999</year><volume>6</volume><fpage>91</fpage><lpage>97</lpage><pub-id pub-id-type="pmid">10341880</pub-id><pub-id pub-id-type="doi">10.1038/sj.gt.3300819</pub-id></citation></ref><ref id="B62"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lorite</surname><given-names>MJ</given-names></name><name><surname>Thompson</surname><given-names>MG</given-names></name><name><surname>Drake</surname><given-names>JL</given-names></name><name><surname>Carling</surname><given-names>G</given-names></name><name><surname>Tisdale</surname><given-names>MJ</given-names></name></person-group><article-title>Mechanism of muscle protein degradation induced by a cancer cachectic factor</article-title><source>Br J Cancer</source><year>1998</year><volume>78</volume><fpage>850</fpage><lpage>856</lpage><comment>(*First description of PIF)</comment><pub-id pub-id-type="pmid">9764574</pub-id></citation></ref><ref id="B63"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lorite</surname><given-names>MJ</given-names></name><name><surname>Smith</surname><given-names>HJ</given-names></name><name><surname>Arnold</surname><given-names>JA</given-names></name><name><surname>Morris</surname><given-names>A</given-names></name><name><surname>Thompson</surname><given-names>MG</given-names></name><name><surname>Tisdale</surname><given-names>MJ</given-names></name></person-group><article-title>Activation of ATP-ubiquitin-dependent proteolysis in skeletal muscle in vivo and murine myoblasts in vitro by a proteolysis-inducing factor (PIF)</article-title><source>Br J Cancer</source><year>2001</year><volume>85</volume><fpage>297</fpage><lpage>302</lpage><pub-id pub-id-type="pmid">11461093</pub-id><pub-id pub-id-type="doi">10.1054/bjoc.2001.1879</pub-id></citation></ref><ref id="B64"><citation citation-type="other"><person-group person-group-type="author"><name><surname>Wyke</surname><given-names>SM</given-names></name><name><surname>Tisdale</surname><given-names>MJ</given-names></name></person-group><article-title>NF-kappaB mediates proteolysis-inducing factor induced protein degradation and expression of the ubiquitin-proteasome system in skeletal muscle</article-title><source>Br J Cancer</source><year>2005</year></citation></ref><ref id="B65"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Russell</surname><given-names>ST</given-names></name><name><surname>Wyke</surname><given-names>SM</given-names></name><name><surname>Tisdale</surname><given-names>MJ</given-names></name></person-group><article-title>Mechanism of induction of muscle protein degradation by angiotensin II</article-title><source>Cell Signal</source><year>2006</year><volume>18</volume><fpage>1087</fpage><lpage>1096</lpage><pub-id pub-id-type="pmid">16257180</pub-id><pub-id pub-id-type="doi">10.1016/j.cellsig.2005.09.009</pub-id></citation></ref><ref id="B66"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hunter</surname><given-names>RB</given-names></name><name><surname>Stevenson</surname><given-names>E</given-names></name><name><surname>Koncarevic</surname><given-names>A</given-names></name><name><surname>Mitchell-Felton</surname><given-names>H</given-names></name><name><surname>Essig</surname><given-names>DA</given-names></name><name><surname>Kandarian</surname><given-names>SC</given-names></name></person-group><article-title>Activation of an alternative NF-kappaB pathway in skeletal muscle during disuse atrophy</article-title><source>Faseb J</source><year>2002</year><volume>16</volume><fpage>529</fpage><lpage>538</lpage><pub-id pub-id-type="pmid">11919155</pub-id><pub-id pub-id-type="doi">10.1096/fj.01-0866com</pub-id></citation></ref><ref id="B67"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McElhinny</surname><given-names>AS</given-names></name><name><surname>Kakinuma</surname><given-names>K</given-names></name><name><surname>Sorimachi</surname><given-names>H</given-names></name><name><surname>Labeit</surname><given-names>S</given-names></name><name><surname>Gregorio</surname><given-names>CC</given-names></name></person-group><article-title>Muscle-specific RING finger-1 interacts with titin to regulate sarcomeric M-line and thick filament structure and may have nuclear functions via its interaction with glucocorticoid modulatory element binding protein-1</article-title><source>J Cell Biol</source><year>2002</year><volume>157</volume><fpage>125</fpage><lpage>136</lpage><pub-id pub-id-type="pmid">11927605</pub-id><pub-id pub-id-type="doi">10.1083/jcb.200108089</pub-id></citation></ref><ref id="B68"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kedar</surname><given-names>V</given-names></name><name><surname>McDonough</surname><given-names>H</given-names></name><name><surname>Arya</surname><given-names>R</given-names></name><name><surname>Li</surname><given-names>HH</given-names></name><name><surname>Rockman</surname><given-names>HA</given-names></name><name><surname>Patterson</surname><given-names>C</given-names></name></person-group><article-title>Muscle-specific RING finger 1 is a bona fide ubiquitin ligase that degrades cardiac troponin I</article-title><source>Proc Natl Acad Sci U S A</source><year>2004</year><volume>101</volume><fpage>18135</fpage><lpage>18140</lpage><pub-id pub-id-type="pmid">15601779</pub-id><pub-id pub-id-type="doi">10.1073/pnas.0404341102</pub-id></citation></ref><ref id="B69"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tintignac</surname><given-names>LA</given-names></name><name><surname>Lagirand</surname><given-names>J</given-names></name><name><surname>Batonnet</surname><given-names>S</given-names></name><name><surname>Sirri</surname><given-names>V</given-names></name><name><surname>Leibovitch</surname><given-names>MP</given-names></name><name><surname>Leibovitch</surname><given-names>SA</given-names></name></person-group><article-title>Degradation of MyoD mediated by the SCF (MAFbx) ubiquitin ligase</article-title><source>J Biol Chem</source><year>2005</year><volume>280</volume><fpage>2847</fpage><lpage>2856</lpage><pub-id pub-id-type="pmid">15531760</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M411346200</pub-id></citation></ref><ref id="B70"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Serrano</surname><given-names>AL</given-names></name><name><surname>Murgia</surname><given-names>M</given-names></name><name><surname>Pallafacchina</surname><given-names>G</given-names></name><name><surname>Calabria</surname><given-names>E</given-names></name><name><surname>Coniglio</surname><given-names>P</given-names></name><name><surname>Lomo</surname><given-names>T</given-names></name><name><surname>Schiaffino</surname><given-names>S</given-names></name></person-group><article-title>Calcineurin controls nerve activity-dependent specification of slow skeletal muscle fibers but not muscle growth</article-title><source>Proc Natl Acad Sci U S A</source><year>2001</year><volume>98</volume><fpage>13108</fpage><lpage>13113</lpage><pub-id pub-id-type="pmid">11606756</pub-id><pub-id pub-id-type="doi">10.1073/pnas.231148598</pub-id></citation></ref><ref id="B71"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Langen</surname><given-names>RC</given-names></name><name><surname>Van Der Velden</surname><given-names>JL</given-names></name><name><surname>Schols</surname><given-names>AM</given-names></name><name><surname>Kelders</surname><given-names>MC</given-names></name><name><surname>Wouters</surname><given-names>EF</given-names></name><name><surname>Janssen-Heininger</surname><given-names>YM</given-names></name></person-group><article-title>Tumor necrosis factor-alpha inhibits myogenic differentiation through MyoD protein destabilization</article-title><source>Faseb J</source><year>2004</year><volume>18</volume><fpage>227</fpage><lpage>237</lpage><pub-id pub-id-type="pmid">14769817</pub-id><pub-id pub-id-type="doi">10.1096/fj.03-0251com</pub-id></citation></ref><ref id="B72"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lecker</surname><given-names>SH</given-names></name><name><surname>Solomon</surname><given-names>V</given-names></name><name><surname>Mitch</surname><given-names>WE</given-names></name><name><surname>Goldberg</surname><given-names>AL</given-names></name></person-group><article-title>Muscle protein breakdown and the critical role of the ubiquitin-proteasome pathway in normal and disease states</article-title><source>J Nutr</source><year>1999</year><volume>129</volume><fpage>227S</fpage><lpage>237S</lpage><pub-id pub-id-type="pmid">9915905</pub-id></citation></ref><ref id="B73"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lecker</surname><given-names>SH</given-names></name><name><surname>Jagoe</surname><given-names>RT</given-names></name><name><surname>Gilbert</surname><given-names>A</given-names></name><name><surname>Gomes</surname><given-names>M</given-names></name><name><surname>Baracos</surname><given-names>V</given-names></name><name><surname>Bailey</surname><given-names>J</given-names></name><name><surname>Price</surname><given-names>SR</given-names></name><name><surname>Mitch</surname><given-names>WE</given-names></name><name><surname>Goldberg</surname><given-names>AL</given-names></name></person-group><article-title>Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression</article-title><source>Faseb J</source><year>2004</year><volume>18</volume><fpage>39</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">14718385</pub-id><pub-id pub-id-type="doi">10.1096/fj.03-0610com</pub-id></citation></ref><ref id="B74"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Adegoke</surname><given-names>OA</given-names></name><name><surname>Bedard</surname><given-names>N</given-names></name><name><surname>Roest</surname><given-names>HP</given-names></name><name><surname>Wing</surname><given-names>SS</given-names></name></person-group><article-title>Ubiquitin-conjugating enzyme E2(14k)/HR6B is dispensable for increased protein catabolism in muscle of fasted mice</article-title><source>Am J Physiol Endocrinol Metab</source><year>2002</year><volume>283</volume><fpage>E482</fpage><lpage>489</lpage><pub-id pub-id-type="pmid">12169441</pub-id></citation></ref><ref id="B75"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kwon</surname><given-names>YT</given-names></name><name><surname>Xia</surname><given-names>Z</given-names></name><name><surname>Davydov</surname><given-names>IV</given-names></name><name><surname>Lecker</surname><given-names>SH</given-names></name><name><surname>Varshavsky</surname><given-names>A</given-names></name></person-group><article-title>Construction and analysis of mouse strains lacking the ubiquitin ligase UBR1 (E3alpha) of the N-end rule pathway</article-title><source>Mol Cell Biol</source><year>2001</year><volume>21</volume><fpage>8007</fpage><lpage>8021</lpage><pub-id pub-id-type="pmid">11689692</pub-id><pub-id pub-id-type="doi">10.1128/MCB.21.23.8007-8021.2001</pub-id></citation></ref><ref id="B76"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fulks</surname><given-names>RM</given-names></name><name><surname>Li</surname><given-names>JB</given-names></name><name><surname>Goldberg</surname><given-names>AL</given-names></name></person-group><article-title>Effects of insulin glucose, and amino acids on protein turnover in rat diaphragm</article-title><source>J Biol Chem</source><year>1975</year><volume>250</volume><fpage>290</fpage><lpage>298</lpage><pub-id pub-id-type="pmid">1141208</pub-id></citation></ref><ref id="B77"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Huszar</surname><given-names>G</given-names></name></person-group><article-title>Developmental changes of the primary structure and histidine methylation in rabbit skeletal muscle myosin</article-title><source>Nat New Biol</source><year>1972</year><volume>240</volume><fpage>260</fpage><lpage>264</lpage><pub-id pub-id-type="pmid">4512226</pub-id><pub-id pub-id-type="doi">10.1038/240260a0</pub-id></citation></ref><ref id="B78"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Young</surname><given-names>VR</given-names></name><name><surname>Munro</surname><given-names>HN</given-names></name></person-group><article-title>Ntau-methylhistidine (3-methylhistidine) and muscle protein turnover: an overview</article-title><source>Fed Proc</source><year>1978</year><volume>37</volume><fpage>2291</fpage><lpage>2300</lpage><pub-id pub-id-type="pmid">350635</pub-id></citation></ref><ref id="B79"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Schakman</surname><given-names>O</given-names></name><name><surname>Thissen</surname><given-names>JP</given-names></name></person-group><article-title>Gene therapy with anabolic growth factors to prevent muscle atrophy</article-title><source>Curr Opin Clin Nutr Metab Care</source><year>2006</year><volume>9</volume><fpage>207</fpage><lpage>213</lpage><pub-id pub-id-type="pmid">16607118</pub-id></citation></ref><ref id="B80"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tisdale</surname><given-names>MJ</given-names></name></person-group><article-title>Clinical anticachexia treatments</article-title><source>Nutr Clin Pract</source><year>2006</year><volume>21</volume><fpage>168</fpage><lpage>174</lpage><pub-id pub-id-type="pmid">16556927</pub-id></citation></ref><ref id="B81"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Whitehouse</surname><given-names>AS</given-names></name><name><surname>Smith</surname><given-names>HJ</given-names></name><name><surname>Drake</surname><given-names>JL</given-names></name><name><surname>Tisdale</surname><given-names>MJ</given-names></name></person-group><article-title>Mechanism of attenuation of skeletal muscle protein catabolism in cancer cachexia by eicosapentaenoic acid</article-title><source>Cancer Res</source><year>2001</year><volume>61</volume><fpage>3604</fpage><lpage>3609</lpage><pub-id pub-id-type="pmid">11325828</pub-id></citation></ref><ref id="B82"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moreira</surname><given-names>AL</given-names></name><name><surname>Sampaio</surname><given-names>EP</given-names></name><name><surname>Zmuidzinas</surname><given-names>A</given-names></name><name><surname>Frindt</surname><given-names>P</given-names></name><name><surname>Smith</surname><given-names>KA</given-names></name><name><surname>Kaplan</surname><given-names>G</given-names></name></person-group><article-title>Thalidomide exerts its inhibitory action on tumous necrosis factor by enhancing mRNA degradation</article-title><source>J Exp Med</source><year>1993</year><volume>177</volume><fpage>1675</fpage><lpage>1680</lpage><pub-id pub-id-type="pmid">8496685</pub-id><pub-id pub-id-type="doi">10.1084/jem.177.6.1675</pub-id></citation></ref><ref id="B83"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gordon</surname><given-names>JN</given-names></name><name><surname>Trebble</surname><given-names>TM</given-names></name><name><surname>Ellis</surname><given-names>RD</given-names></name><name><surname>Duncan</surname><given-names>HD</given-names></name><name><surname>Johns</surname><given-names>T</given-names></name><name><surname>Goggin</surname><given-names>PM</given-names></name></person-group><article-title>Thalidomide in the treatment of cancer cachexia: a randomised placebo controlled trial</article-title><source>Gut</source><year>2005</year><volume>54</volume><fpage>540</fpage><lpage>545</lpage><pub-id pub-id-type="pmid">15753541</pub-id><pub-id pub-id-type="doi">10.1136/gut.2004.047563</pub-id></citation></ref><ref id="B84"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Boddaert</surname><given-names>MS</given-names></name><name><surname>Gerritsen</surname><given-names>WR</given-names></name><name><surname>Pinedo</surname><given-names>HM</given-names></name></person-group><article-title>On our way to targeted therapy for cachexia in cancer?</article-title><source>Curr Opin Oncol</source><year>2006</year><volume>18</volume><fpage>335</fpage><lpage>340</lpage><pub-id pub-id-type="pmid">16721127</pub-id><pub-id pub-id-type="doi">10.1097/01.cco.0000228738.85626.ac</pub-id></citation></ref><ref id="B85"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dezube</surname><given-names>BJ</given-names></name><name><surname>Sherman</surname><given-names>ML</given-names></name><name><surname>Fridovich-Keil</surname><given-names>JL</given-names></name><name><surname>Allen-Ryan</surname><given-names>J</given-names></name><name><surname>Pardee</surname><given-names>AB</given-names></name></person-group><article-title>Down-regulation of tumor necrosis factor expression by pentoxifylline in cancer patients: a pilot study</article-title><source>Cancer Immunol Immunother</source><year>1993</year><volume>36</volume><fpage>57</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">7678547</pub-id><pub-id pub-id-type="doi">10.1007/BF01789132</pub-id></citation></ref><ref id="B86"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Combaret</surname><given-names>L</given-names></name><name><surname>Ralliere</surname><given-names>C</given-names></name><name><surname>Taillandier</surname><given-names>D</given-names></name><name><surname>Tanaka</surname><given-names>K</given-names></name><name><surname>Attaix</surname><given-names>D</given-names></name></person-group><article-title>Manipulation of the ubiquitin-proteasome pathway in cachexia: pentoxifylline suppresses the activation of 20S and 26S proteasomes in muscles from tumor-bearing rats</article-title><source>Mol Biol Rep</source><year>1999</year><volume>26</volume><fpage>95</fpage><lpage>101</lpage><pub-id pub-id-type="pmid">10363654</pub-id><pub-id pub-id-type="doi">10.1023/A:1006955832323</pub-id></citation></ref><ref id="B87"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Goldberg</surname><given-names>RM</given-names></name><name><surname>Loprinzi</surname><given-names>CL</given-names></name><name><surname>Mailliard</surname><given-names>JA</given-names></name><name><surname>O'Fallon</surname><given-names>JR</given-names></name><name><surname>Krook</surname><given-names>JE</given-names></name><name><surname>Ghosh</surname><given-names>C</given-names></name><name><surname>Hestorff</surname><given-names>RD</given-names></name><name><surname>Chong</surname><given-names>SF</given-names></name><name><surname>Reuter</surname><given-names>NF</given-names></name><name><surname>Shanahan</surname><given-names>TG</given-names></name></person-group><article-title>Pentoxifylline for treatment of cancer anorexia and cachexia? A randomized, double-blind, placebo-controlled trial</article-title><source>J Clin Oncol</source><year>1995</year><volume>13</volume><fpage>2856</fpage><lpage>2859</lpage><pub-id pub-id-type="pmid">7595749</pub-id></citation></ref><ref id="B88"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Combaret</surname><given-names>L</given-names></name><name><surname>Tilignac</surname><given-names>T</given-names></name><name><surname>Claustre</surname><given-names>A</given-names></name><name><surname>Voisin</surname><given-names>L</given-names></name><name><surname>Taillandier</surname><given-names>D</given-names></name><name><surname>Obled</surname><given-names>C</given-names></name><name><surname>Tanaka</surname><given-names>K</given-names></name><name><surname>Attaix</surname><given-names>D</given-names></name></person-group><article-title>Torbafylline (HWA 448) inhibits enhanced skeletal muscle ubiquitin- proteasome-dependent proteolysis in cancer and septic rats</article-title><source>Biochem J</source><year>2002</year><volume>361</volume><fpage>185</fpage><lpage>192</lpage><pub-id pub-id-type="pmid">11772390</pub-id><pub-id pub-id-type="doi">10.1042/0264-6021:3610185</pub-id></citation></ref><ref id="B89"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yimlamai</surname><given-names>T</given-names></name><name><surname>Dodd</surname><given-names>SL</given-names></name><name><surname>Borst</surname><given-names>SE</given-names></name><name><surname>Park</surname><given-names>S</given-names></name></person-group><article-title>Clenbuterol induces muscle-specific attenuation of atrophy through effects on the ubiquitin-proteasome pathway</article-title><source>J Appl Physiol</source><year>2005</year><volume>99</volume><fpage>71</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">15774696</pub-id><pub-id pub-id-type="doi">10.1152/japplphysiol.00448.2004</pub-id></citation></ref><ref id="B90"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ryall</surname><given-names>JG</given-names></name><name><surname>Plant</surname><given-names>DR</given-names></name><name><surname>Gregorevic</surname><given-names>P</given-names></name><name><surname>Sillence</surname><given-names>MN</given-names></name><name><surname>Lynch</surname><given-names>GS</given-names></name></person-group><article-title>Beta 2-agonist administration reverses muscle wasting and improves muscle function in aged rats</article-title><source>J Physiol</source><year>2004</year><volume>555</volume><fpage>175</fpage><lpage>188</lpage><pub-id pub-id-type="pmid">14617677</pub-id><pub-id pub-id-type="doi">10.1113/jphysiol.2003.056770</pub-id></citation></ref><ref id="B91"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Busquets</surname><given-names>S</given-names></name><name><surname>Figueras</surname><given-names>MT</given-names></name><name><surname>Fuster</surname><given-names>G</given-names></name><name><surname>Almendro</surname><given-names>V</given-names></name><name><surname>Moore-Carrasco</surname><given-names>R</given-names></name><name><surname>Ametller</surname><given-names>E</given-names></name><name><surname>Argiles</surname><given-names>JM</given-names></name><name><surname>Lopez-Soriano</surname><given-names>FJ</given-names></name></person-group><article-title>Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting</article-title><source>Cancer Res</source><year>2004</year><volume>64</volume><fpage>6725</fpage><lpage>6731</lpage><pub-id pub-id-type="pmid">15374990</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-04-0425</pub-id></citation></ref><ref id="B92"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hoffman</surname><given-names>RJ</given-names></name><name><surname>Hoffman</surname><given-names>RS</given-names></name><name><surname>Freyberg</surname><given-names>CL</given-names></name><name><surname>Poppenga</surname><given-names>RH</given-names></name><name><surname>Nelson</surname><given-names>LS</given-names></name></person-group><article-title>Clenbuterol ingestion causing prolonged tachycardia, hypokalemia, and hypophosphatemia with confirmation by quantitative levels</article-title><source>J Toxicol Clin Toxicol</source><year>2001</year><volume>39</volume><fpage>339</fpage><lpage>344</lpage><pub-id pub-id-type="pmid">11527226</pub-id><pub-id pub-id-type="doi">10.1081/CLT-100105152</pub-id></citation></ref><ref id="B93"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wyke</surname><given-names>SM</given-names></name><name><surname>Russell</surname><given-names>ST</given-names></name><name><surname>Tisdale</surname><given-names>MJ</given-names></name></person-group><article-title>Induction of proteasome expression in skeletal muscle is attenuated by inhibitors of NF-kappaB activation</article-title><source>Br J Cancer</source><year>2004</year><volume>91</volume><fpage>1742</fpage><lpage>1750</lpage><pub-id pub-id-type="pmid">15477867</pub-id></citation></ref><ref id="B94"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fischer</surname><given-names>D</given-names></name><name><surname>Gang</surname><given-names>G</given-names></name><name><surname>Pritts</surname><given-names>T</given-names></name><name><surname>Hasselgren</surname><given-names>PO</given-names></name></person-group><article-title>Sepsis-induced muscle proteolysis is prevented by a proteasome inhibitor in vivo</article-title><source>Biochem Biophys Res Commun</source><year>2000</year><volume>270</volume><fpage>215</fpage><lpage>221</lpage><pub-id pub-id-type="pmid">10733930</pub-id><pub-id pub-id-type="doi">10.1006/bbrc.2000.2398</pub-id></citation></ref><ref id="B95"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chauhan</surname><given-names>D</given-names></name><name><surname>Hideshima</surname><given-names>T</given-names></name><name><surname>Anderson</surname><given-names>KC</given-names></name></person-group><article-title>Proteasome inhibition in multiple myeloma: therapeutic implication</article-title><source>Annu Rev Pharmacol Toxicol</source><year>2005</year><volume>45</volume><fpage>465</fpage><lpage>476</lpage><pub-id pub-id-type="pmid">15822185</pub-id><pub-id pub-id-type="doi">10.1146/annurev.pharmtox.45.120403.100037</pub-id></citation></ref><ref id="B96"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Jones</surname><given-names>SW</given-names></name><name><surname>Hill</surname><given-names>RJ</given-names></name><name><surname>Krasney</surname><given-names>PA</given-names></name><name><surname>O'Conner</surname><given-names>B</given-names></name><name><surname>Peirce</surname><given-names>N</given-names></name><name><surname>Greenhaff</surname><given-names>PL</given-names></name></person-group><article-title>Disuse atrophy and exercise rehabilitation in humans profoundly affects the expression of genes associated with the regulation of skeletal muscle mass</article-title><source>Faseb J</source><year>2004</year><volume>18</volume><fpage>1025</fpage><lpage>1027</lpage><pub-id pub-id-type="pmid">15084522</pub-id></citation></ref><ref id="B97"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Moore-Carrasco</surname><given-names>R</given-names></name></person-group><article-title>The AP-1/cJUN signaling cascade is involved in muscle differentiation: implications in muscle wasting during cancer cachexia</article-title><source>FEBS Lett</source><year>2006</year><volume>580</volume><fpage>691</fpage><lpage>696</lpage><pub-id pub-id-type="pmid">16412434</pub-id><pub-id pub-id-type="doi">10.1016/j.febslet.2005.12.084</pub-id></citation></ref><ref id="B98"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>YP</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>John</surname><given-names>J</given-names></name><name><surname>Moylan</surname><given-names>J</given-names></name><name><surname>Jin</surname><given-names>B</given-names></name><name><surname>Mann</surname><given-names>DL</given-names></name><name><surname>Reid</surname><given-names>MB</given-names></name></person-group><article-title>TNF-alpha acts via p38 MAPK to stimulate expression of the ubiquitin ligase atrogin1/MAFbx in skeletal muscle</article-title><source>Faseb J</source><year>2005</year><volume>19</volume><fpage>362</fpage><lpage>370</lpage><pub-id pub-id-type="pmid">15746179</pub-id><pub-id pub-id-type="doi">10.1096/fj.04-2364com</pub-id></citation></ref><ref id="B99"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nalepa</surname><given-names>G</given-names></name><name><surname>Rolfe</surname><given-names>M</given-names></name><name><surname>Harper</surname><given-names>JW</given-names></name></person-group><article-title>Drug discovery in the ubiquitin-proteasome system</article-title><source>Nat Rev Drug Discov</source><year>2006</year><volume>5</volume><fpage>596</fpage><lpage>613</lpage><pub-id pub-id-type="pmid">16816840</pub-id><pub-id pub-id-type="doi">10.1038/nrd2056</pub-id></citation></ref><ref id="B100"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Khal</surname><given-names>J</given-names></name><name><surname>Wyke</surname><given-names>SM</given-names></name><name><surname>Russell</surname><given-names>ST</given-names></name><name><surname>Hine</surname><given-names>AV</given-names></name><name><surname>Tisdale</surname><given-names>MJ</given-names></name></person-group><article-title>Expression of the ubiquitin-proteasome pathway and muscle loss in experimental cancer cachexia</article-title><source>Br J Cancer</source><year>2005</year><volume>93</volume><fpage>774</fpage><lpage>780</lpage><pub-id pub-id-type="pmid">16160695</pub-id><pub-id pub-id-type="doi">10.1038/sj.bjc.6602780</pub-id></citation></ref><ref id="B101"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wray</surname><given-names>CJ</given-names></name><name><surname>Mammen</surname><given-names>JM</given-names></name><name><surname>Hershko</surname><given-names>DD</given-names></name><name><surname>Hasselgren</surname><given-names>PO</given-names></name></person-group><article-title>Sepsis upregulates the gene expression of multiple ubiquitin ligases in skeletal muscle</article-title><source>Int J Biochem Cell Biol</source><year>2003</year><volume>35</volume><fpage>698</fpage><lpage>705</lpage><pub-id pub-id-type="pmid">12672461</pub-id><pub-id pub-id-type="doi">10.1016/S1357-2725(02)00341-2</pub-id></citation></ref><ref id="B102"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Voisin</surname><given-names>L</given-names></name><name><surname>Breuille</surname><given-names>D</given-names></name><name><surname>Combaret</surname><given-names>L</given-names></name><name><surname>Pouyet</surname><given-names>C</given-names></name><name><surname>Taillandier</surname><given-names>D</given-names></name><name><surname>Aurousseau</surname><given-names>E</given-names></name><name><surname>Obled</surname><given-names>C</given-names></name><name><surname>Attaix</surname><given-names>D</given-names></name></person-group><article-title>Muscle wasting in a rat model of long-lasting sepsis results from the activation of lysosomal, Ca2+-activated, and ubiquitin-proteasome proteolytic pathways</article-title><source>J Clin Invest</source><year>1996</year><volume>97</volume><fpage>1610</fpage><lpage>1617</lpage><pub-id pub-id-type="pmid">8601625</pub-id></citation></ref><ref id="B103"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Taillandier</surname><given-names>D</given-names></name><name><surname>Aurousseau</surname><given-names>E</given-names></name><name><surname>Combaret</surname><given-names>L</given-names></name><name><surname>Guezennec</surname><given-names>CY</given-names></name><name><surname>Attaix</surname><given-names>D</given-names></name></person-group><article-title>Regulation of proteolysis during reloading of the unweighted soleus muscle</article-title><source>Int J Biochem Cell Biol</source><year>2003</year><volume>35</volume><fpage>665</fpage><lpage>675</lpage><pub-id pub-id-type="pmid">12672458</pub-id><pub-id pub-id-type="doi">10.1016/S1357-2725(03)00004-9</pub-id></citation></ref><ref id="B104"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Batt</surname><given-names>J</given-names></name><name><surname>Bain</surname><given-names>J</given-names></name><name><surname>Goncalves</surname><given-names>J</given-names></name><name><surname>Michalski</surname><given-names>B</given-names></name><name><surname>Plant</surname><given-names>P</given-names></name><name><surname>Fahnestock</surname><given-names>M</given-names></name><name><surname>Woodgett</surname><given-names>J</given-names></name></person-group><article-title>Differential gene expression profiling of short and long term denervated muscle</article-title><source>Faseb J</source><year>2006</year><volume>20</volume><fpage>115</fpage><lpage>117</lpage><pub-id pub-id-type="pmid">16291642</pub-id></citation></ref><ref id="B105"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lecker</surname><given-names>SH</given-names></name><name><surname>Solomon</surname><given-names>V</given-names></name><name><surname>Price</surname><given-names>SR</given-names></name><name><surname>Kwon</surname><given-names>YT</given-names></name><name><surname>Mitch</surname><given-names>WE</given-names></name><name><surname>Goldberg</surname><given-names>AL</given-names></name></person-group><article-title>Ubiquitin conjugation by the N-end rule pathway and mRNAs for its components increase in muscles of diabetic rats</article-title><source>J Clin Invest</source><year>1999</year><volume>104</volume><fpage>1411</fpage><lpage>1420</lpage><pub-id pub-id-type="pmid">10562303</pub-id></citation></ref><ref id="B106"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Duan</surname><given-names>X</given-names></name><name><surname>Berthiaume</surname><given-names>F</given-names></name><name><surname>Yarmush</surname><given-names>D</given-names></name><name><surname>Yarmush</surname><given-names>ML</given-names></name></person-group><article-title>Proteomic analysis of altered protein expression in skeletal muscle of rats in a hypermetabolic state induced by burn sepsis</article-title><source>Biochem J</source><year>2006</year><volume>397</volume><fpage>149</fpage><lpage>158</lpage><pub-id pub-id-type="pmid">16483253</pub-id><pub-id pub-id-type="doi">10.1042/BJ20051710</pub-id></citation></ref><ref id="B107"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pereira</surname><given-names>C</given-names></name><name><surname>Murphy</surname><given-names>K</given-names></name><name><surname>Jeschke</surname><given-names>M</given-names></name><name><surname>Herndon</surname><given-names>DN</given-names></name></person-group><article-title>Post burn muscle wasting and the effects of treatments</article-title><source>Int J Biochem Cell Biol</source><year>2005</year><volume>37</volume><fpage>1948</fpage><lpage>1961</lpage><pub-id pub-id-type="pmid">16109499</pub-id><pub-id pub-id-type="doi">10.1016/j.biocel.2005.05.009</pub-id></citation></ref><ref id="B108"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>SY</given-names></name><name><surname>Chen</surname><given-names>WY</given-names></name><name><surname>Lee</surname><given-names>FY</given-names></name><name><surname>Huang</surname><given-names>CJ</given-names></name><name><surname>Sheu</surname><given-names>WH</given-names></name></person-group><article-title>Activation of ubiquitin-proteasome pathway is involved in skeletal muscle wasting in a rat model with biliary cirrhosis: potential role of TNF-alpha</article-title><source>Am J Physiol Endocrinol Metab</source><year>2005</year><volume>288</volume><fpage>E493</fpage><lpage>501</lpage><pub-id pub-id-type="pmid">15522995</pub-id><pub-id pub-id-type="doi">10.1152/ajpendo.00186.2004</pub-id></citation></ref><ref id="B109"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dasarathy</surname><given-names>S</given-names></name><name><surname>Dodig</surname><given-names>M</given-names></name><name><surname>Muc</surname><given-names>SM</given-names></name><name><surname>Kalhan</surname><given-names>SC</given-names></name><name><surname>McCullough</surname><given-names>AJ</given-names></name></person-group><article-title>Skeletal muscle atrophy is associated with an increased expression of myostatin and impaired satellite cell function in the portacaval anastamosis rat</article-title><source>Am J Physiol Gastrointest Liver Physiol</source><year>2004</year><volume>287</volume><fpage>G1124</fpage><lpage>1130</lpage><pub-id pub-id-type="pmid">15256363</pub-id><pub-id pub-id-type="doi">10.1152/ajpgi.00202.2004</pub-id></citation></ref><ref id="B110"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kee</surname><given-names>AJ</given-names></name><name><surname>Combaret</surname><given-names>L</given-names></name><name><surname>Tilignac</surname><given-names>T</given-names></name><name><surname>Souweine</surname><given-names>B</given-names></name><name><surname>Aurousseau</surname><given-names>E</given-names></name><name><surname>Dalle</surname><given-names>M</given-names></name><name><surname>Taillandier</surname><given-names>D</given-names></name><name><surname>Attaix</surname><given-names>D</given-names></name></person-group><article-title>Ubiquitin-proteasome-dependent muscle proteolysis responds slowly to insulin release and refeeding in starved rats</article-title><source>J Physiol</source><year>2003</year><volume>546</volume><fpage>765</fpage><lpage>776</lpage><pub-id pub-id-type="pmid">12563002</pub-id><pub-id pub-id-type="doi">10.1113/jphysiol.2002.032367</pub-id></citation></ref><ref id="B111"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Argiles</surname><given-names>JM</given-names></name><name><surname>Busquets</surname><given-names>S</given-names></name><name><surname>Garcia-Martinez</surname><given-names>C</given-names></name><name><surname>Lopez-Soriano</surname><given-names>FJ</given-names></name></person-group><article-title>Mediators involved in the cancer anorexia-cachexia syndrome: past, present, and future</article-title><source>Nutrition</source><year>2005</year><volume>21</volume><fpage>977</fpage><lpage>985</lpage><pub-id pub-id-type="pmid">16043325</pub-id></citation></ref><ref id="B112"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Miers</surname><given-names>WR</given-names></name><name><surname>Wei</surname><given-names>L</given-names></name><name><surname>Barrett</surname><given-names>EJ</given-names></name></person-group><article-title>The ubiquitin-proteasome proteolytic pathway in heart vs skeletal muscle: effects of acute diabetes</article-title><source>Biochem Biophys Res Commun</source><year>2000</year><volume>276</volume><fpage>1255</fpage><lpage>1260</lpage><pub-id pub-id-type="pmid">11027619</pub-id><pub-id pub-id-type="doi">10.1006/bbrc.2000.3609</pub-id></citation></ref><ref id="B113"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>J</given-names></name><name><surname>Mitch</surname><given-names>WE</given-names></name></person-group><article-title>Identification of pathways controlling muscle protein metabolism in uremia and other catabolic conditions</article-title><source>Curr Opin Nephrol Hypertens</source><year>2005</year><volume>14</volume><fpage>378</fpage><lpage>382</lpage><pub-id pub-id-type="pmid">15931008</pub-id></citation></ref><ref id="B114"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Roest</surname><given-names>HP</given-names></name><name><surname>van Klaveren</surname><given-names>J</given-names></name><name><surname>de Wit</surname><given-names>J</given-names></name><name><surname>van Gurp</surname><given-names>CG</given-names></name><name><surname>Koken</surname><given-names>MH</given-names></name><name><surname>Vermey</surname><given-names>M</given-names></name><name><surname>van Roijen</surname><given-names>JH</given-names></name><name><surname>Hoogerbrugge</surname><given-names>JW</given-names></name><name><surname>Vreeburg</surname><given-names>JT</given-names></name><name><surname>Baarends</surname><given-names>WM</given-names></name><name><surname>Bootsma</surname><given-names>D</given-names></name><name><surname>Grootegoed</surname><given-names>JA</given-names></name><name><surname>Hoeijmakers</surname><given-names>JH</given-names></name></person-group><article-title>Inactivation of the HR6B ubiquitin-conjugating DNA repair enzyme in mice causes male sterility associated with chromatin modification</article-title><source>Cell</source><year>1996</year><volume>86</volume><fpage>799</fpage><lpage>810</lpage><pub-id pub-id-type="pmid">8797826</pub-id><pub-id pub-id-type="doi">10.1016/S0092-8674(00)80154-3</pub-id></citation></ref><ref id="B115"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Messina</surname><given-names>S</given-names></name><name><surname>Bitto</surname><given-names>A</given-names></name><name><surname>Aguennouz</surname><given-names>M</given-names></name><name><surname>Minutoli</surname><given-names>L</given-names></name><name><surname>Monici</surname><given-names>MC</given-names></name><name><surname>Altavilla</surname><given-names>D</given-names></name><name><surname>Squadrito</surname><given-names>F</given-names></name><name><surname>Vita</surname><given-names>G</given-names></name></person-group><article-title>Nuclear factor kappa-B blockade reduces skeletal muscle degeneration and enhances muscle function in Mdx mice</article-title><source>Exp Neurol</source><year>2006</year><volume>198</volume><fpage>234</fpage><lpage>241</lpage><pub-id pub-id-type="pmid">16410003</pub-id><pub-id pub-id-type="doi">10.1016/j.expneurol.2005.11.021</pub-id></citation></ref><ref id="B116"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kamei</surname><given-names>Y</given-names></name><name><surname>Miura</surname><given-names>S</given-names></name><name><surname>Suzuki</surname><given-names>M</given-names></name><name><surname>Kai</surname><given-names>Y</given-names></name><name><surname>Mizukami</surname><given-names>J</given-names></name><name><surname>Taniguchi</surname><given-names>T</given-names></name><name><surname>Mochida</surname><given-names>K</given-names></name><name><surname>Hata</surname><given-names>T</given-names></name><name><surname>Matsuda</surname><given-names>J</given-names></name><name><surname>Aburatani</surname><given-names>H</given-names></name><name><surname>Nishino</surname><given-names>I</given-names></name><name><surname>Ezaki</surname><given-names>O</given-names></name></person-group><article-title>Skeletal muscle FOXO1 (FKHR) transgenic mice have less skeletal muscle mass, down-regulated Type I (slow twitch/red muscle) fiber genes, and impaired glycemic control</article-title><source>J Biol Chem</source><year>2004</year><volume>279</volume><fpage>41114</fpage><lpage>41123</lpage><pub-id pub-id-type="pmid">15272020</pub-id><pub-id pub-id-type="doi">10.1074/jbc.M400674200</pub-id></citation></ref></ref-list></back></article>


